<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery - Lim, BX - 2016 | Cochrane Library</title> <meta content="Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery - Lim, BX - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006683.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery - Lim, BX - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006683.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006683.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery" name="citation_title"/> <meta content="Blanche X Lim&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="National University Health System" name="citation_author_institution"/> <meta content="Chris HL Lim&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Royal Melbourne Hospital" name="citation_author_institution"/> <meta content="Dawn K Lim&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="National University Health System" name="citation_author_institution"/> <meta content="Jennifer R Evans" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Catey Bunce" name="citation_author"/> <meta content="Kings College London" name="citation_author_institution"/> <meta content="Richard Wormald" name="citation_author"/> <meta content="r.wormald@ucl.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD006683.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/11/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006683.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006683.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006683.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; Cataract Extraction [*adverse effects]; Macular Edema [etiology, *prevention &amp; control]; Postoperative Complications [*prevention &amp; control]; Randomized Controlled Trials as Topic; Steroids [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006683.pub3&amp;doi=10.1002/14651858.CD006683.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006683\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006683\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006683.pub3",title:"Prophylactic non\\u2010steroidal anti\\u2010inflammatory drugs for the prevention of macular oedema after cataract surgery",firstPublishedDate:"Nov 1, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006683.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006683.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006683.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006683.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006683.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006683.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006683.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006683.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006683.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006683.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5034 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006683.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/appendices#CD006683-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/table_n/CD006683StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/table_n/CD006683StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#CD006683-cr-0002">Blanche X Lim</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#CD006683-cr-0003">Chris HL Lim</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#CD006683-cr-0004">Dawn K Lim</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#CD006683-cr-0005">Jennifer R Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#CD006683-cr-0006">Catey Bunce</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information#CD006683-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Richard Wormald</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information/en#CD006683-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 November 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006683.pub3">https://doi.org/10.1002/14651858.CD006683.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006683-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006683-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006683-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006683-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006683-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006683-abs-0001" lang="en"> <section id="CD006683-sec-0001"> <h3 class="title" id="CD006683-sec-0001">Background</h3> <p>Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self‐limiting with spontaneous resolution, but a small proportion of people with chronic persistent MO may be difficult to treat. Chronic oedema may lead to the formation of cystic spaces in the retina termed 'cystoid macular oedema' (CMO). Non‐steroidal anti‐inflammatory drugs (NSAIDs) are commonly used in cataract surgery and may reduce the chances of developing MO. </p> </section> <section id="CD006683-sec-0002"> <h3 class="title" id="CD006683-sec-0002">Objectives</h3> <p>The aim of this review is to answer the question: is there evidence to support the prophylactic use of topical NSAIDs either in addition to, or instead of, topical steroids postoperatively to reduce the incidence of macular oedema (MO) and associated visual morbidity. </p> </section> <section id="CD006683-sec-0003"> <h3 class="title" id="CD006683-sec-0003">Search methods</h3> <p>We searched a number of electronic databases including CENTRAL, MEDLINE and Embase. Date last searched 2 September 2016. </p> </section> <section id="CD006683-sec-0004"> <h3 class="title" id="CD006683-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in which adult participants had undergone surgery for age‐related cataract. We included participants irrespective of their baseline risk of MO, in particular we included people with diabetes and uveitis. We included trials of preoperative and/or postoperative topical NSAIDs in conjunction with postoperative topical steroids. The comparator was postoperative topical steroids alone. A secondary comparison was preoperative and/or postoperative topical NSAIDs alone versus postoperative topical steroids alone. </p> </section> <section id="CD006683-sec-0005"> <h3 class="title" id="CD006683-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies for inclusion, assessed risk of bias and extracted data using standard methods expected by Cochrane. We pooled data using a random‐effects model. We graded the certainty of the evidence using GRADE and considered the following: risk of bias of included studies, precision of the effect estimate, consistency of effects between studies, directness of the outcome measure and publication bias. </p> </section> <section id="CD006683-sec-0006"> <h3 class="title" id="CD006683-sec-0006">Main results</h3> <p>We identified 34 studies that were conducted in the Americas, Europe, the Eastern Mediterranean region and South‐East Asia. Over 5000 people were randomised in these trials. The majority of studies enrolled one eye per participant; a small subset (4 trials) enrolled a proportion of people with bilateral surgery. Twenty‐eight studies compared NSAIDs plus steroids with steroids alone. Six studies compared NSAIDs with steroids. A variety of NSAIDs were used, including ketorolac, diclofenac, nepafenac, indomethacin, bromfenac, flurbiprofen and pranopfen. Follow‐up ranged from one to 12 months. In general, the studies were poorly reported. We did not judge any of the studies at low risk of bias in all domains. Six studies were funded by industry, seven studies were funded from non‐industry sources, and the rest of the studies did not report the source of funding. </p> <p>There was low‐certainty evidence that people receiving topical NSAIDs in combination with steroids may have a lower risk of poor vision due to MO at three months after cataract surgery compared with people receiving steroids alone (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.23 to 0.76; eyes = 1360; studies = 5; I<sup>2</sup> = 5%). We judged this to be low‐certainty evidence because of risk of bias in the included studies and indirectness, as the extent of visual loss was not always clear. Only one study reported poor vision due to MO at 12 months and we judged this to be very low‐certainty evidence as there were only two events. Quality of life was only reported in one of the 34 studies comparing NSAIDs plus steroids versus steroids alone, and it was not fully reported, other than to comment on lack of differences between groups. There was evidence of a reduced risk of MO with NSAIDs at three months after surgery, but we judged this to be low‐certainty due to risk of bias and publication bias (RR 0.40, 95% CI 0.32 to 0.49; eyes = 3638; studies = 21). There was inconsistent evidence on central retinal thickness at three months (I<sup>2</sup> = 87%). Results ranged from ‐30.9 µm in favour of NSAIDs plus steroids to 7.44 µm in favour of steroids alone. Similarly, data on best corrected visual acuity (BCVA) were inconsistent, but nine out of 10 trials reporting this outcome found between‐group differences in visual acuity of less than 0.1 logMAR. </p> <p>None of the six studies comparing NSAIDs alone with steroids reported on poor vision due to MO at three or 12 months. There was low‐certainty evidence that central retinal thickness was lower in the NSAIDs group at three months (mean difference (MD) ‐22.64 µm, 95% CI ‐38.86 to ‐6.43; eyes = 121; studies = 2). Five studies reported on MO and showed a reduced risk with NSAIDs, but we judged this evidence to be of low‐certainty (RR 0.27, 95% CI 0.18 to 0.41; eyes = 520). Three studies reported BCVA at three months and the results of these trials were inconsistent, but all three studies found differences of less than 0.1 logMAR between groups. </p> <p>We did not note any major adverse events ‐ the main consistent observation was burning or stinging sensation with the use of NSAIDs. </p> </section> <section id="CD006683-sec-0007"> <h3 class="title" id="CD006683-sec-0007">Authors' conclusions</h3> <p>Using topical NSAIDs may reduce the risk of developing macular oedema after cataract surgery, although it is possible that current estimates as to the size of this reduction are exaggerated. It is unclear the extent to which this reduction has an impact on the visual function and quality of life of patients. There is little evidence to suggest any important effect on vision after surgery. The value of adding topical NSAIDs to steroids, or using them as an alternative to topical steroids, with a view to reducing the risk of poor visual outcome after cataract surgery is therefore uncertain. Future trials should address the remaining clinical uncertainty of whether prophylactic topical NSAIDs are of benefit, particularly with respect to longer‐term follow‐up (at least to 12 months), and should be large enough to detect reduction in the risk of the outcome of most interest to patients, which is chronic macular oedema leading to visual loss. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006683-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006683-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006683-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006683-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006683-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006683-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006683-abs-0003" lang="en"> <h3>Prophylactic non‐steroidal anti‐inflammatory drugs (NSAIDs) for the prevention of macular oedema after cataract surgery </h3> <p><b>What is the aim of this review?</b> <br/> The aim of this Cochrane Review was to find out if NSAID eye drops can prevent a sight‐threatening complication of cataract surgery (swelling at the back of the eye, known as macular oedema). Cochrane researchers collected and analysed all relevant studies to answer this question and found 34 studies. </p> <p><b>Key messages</b> <br/> There is only low‐certainty evidence to support the use of NSAID eye drops to prevent macular oedema affecting vision after cataract surgery. </p> <p><b>What was studied in the review?</b> <br/> There is a clear lens in the eye that focuses the light on the back of the eye. As people get older this lens can become cloudy. A cloudy lens is known as a cataract. Doctors can remove the cataract and replace it with an artificial lens. This is usually a very successful operation. Occasionally, people having cataract surgery can get swelling at the back of the eye after the operation. This swelling is known as macular oedema. It usually gets better on its own accord, but if it persists it can result in poor vision. </p> <p>NSAIDs are a medication that can treat inflammation. They may be able to reduce the chances of this swelling happening. The NSAIDs studied in this review were eye drops. </p> <p><b>What are the main results of the review?</b> <br/> The review authors found 34 relevant studies. These studies were conducted in all parts of the world including the Americas, Europe, the Eastern Mediterranean region and South‐East Asia. Most (28) of these studies compared NSAIDs combined with steroids against steroids alone. Some of the studies (6) compared NSAIDs with steroids alone. A variety of NSAIDs were used, including ketorolac, diclofenac, nepafenac, indomethacin, bromfenac, pranopfen and flurbiprofen. People taking part in these trials were followed up from between one and 12 months. Most studies only followed up to two months or less. Six studies were funded by industry; seven studies were funded from non‐industry sources and the rest of the studies did not report the source of funding. </p> <p>There was low‐certainty evidence that NSAIDs reduce the chance of poor vision due to macular oedema three months after cataract surgery. Only one study reported on poor vision due to macular oedema at 12 months and we judged this to have very low‐certainty of evidence. </p> <p>Using NSAIDs was associated with a reduced risk of macular oedema but the review authors judged this to be low‐certainty. </p> <p>Inconsistent results were seen for some measurements of macular oedema, such as the thickness of the tissue at the back of the eye (central retinal thickness) at three months after surgery. This measurement was not reported by any studies at 12 months after surgery. </p> <p>Similarly, inconsistent results were seen for vision measurement (visual acuity) but most studies found small differences between people given NSAIDs and people not given NSAIDs. </p> <p>Only one study reported quality of life, and this suggested little impact of NSAIDs on quality of life. </p> <p>Adverse events mainly consisted of a burning or stinging sensation.</p> <p><b>How up‐to‐date is this review?</b> <br/> The review authors searched for studies that had been published up to 2 September 2016. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006683-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006683-sec-0106"></div> <h3 class="title" id="CD006683-sec-0107">Implications for practice</h3> <section id="CD006683-sec-0107"> <p>Using topical NSAIDs may reduce the risk of developing macular oedema after cataract surgery, although it is possible that current estimates as to the size of this reduction are exaggerated due to selective non‐reporting of negative studies. It is unclear the extent to which this reduction has an impact on the visual function and quality of life of patients. There is little evidence to suggest any important effect on vision after surgery </p> <p>The value of adding topical NSAIDs to steroids, or using them as an alternative to topical steroids with a view to reducing the risk of poor visual outcome after cataract surgery is uncertain. This is reflected in wide variations in modern practice. The role of the relative effectiveness and safety of NSAIDs as an alternative to steroids in the control of post operative inflammation is being addressed in another Cochrane Review (<a href="./references#CD006683-bbs2-0069" title="GonzalesJA , GritzDC , ChannaR , QuintoGG , KimA , ChuckRS . Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD010516] ">Gonzales 2013</a>). </p> </section> <h3 class="title" id="CD006683-sec-0108">Implications for research</h3> <section id="CD006683-sec-0108"> <p>Future trials should address the remaining clinical uncertainty of whether prophylactic topical NSAIDs are of benefit, particularly with respect to longer‐term follow‐up (at least to 12 months), and should be large enough to detect to detect reduction in the risk of the outcome of most interest to patients, which is chronic macular oedema leading to visual loss. They should be rigorously conducted and double‐masked. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006683-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006683-sec-0022"></div> <div class="table" id="CD006683-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAIDS plus steroids compared with steroids for the prevention of macular oedema after cataract surgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NSAIDs plus steroids compared with steroids for the prevention of macular oedema after cataract surgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people having cataract surgery </p> <p><b>Setting:</b> eye hospital<br/> <b>Intervention:</b> NSAIDs plus steroids<br/> <b>Comparison:</b> steroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs plus steroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision due to MO at 3 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (17 to 56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.41<br/> (0.23 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1360<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision due to MO at 12 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (2 to 407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.32<br/> (0.09 to 20.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life at 3 months after surgery</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in 1 study only using COMTOL questionnaire. Data not fully reported but no significant differences in terms of quality of life, compliance and satisfaction scores. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central retinal thickness at 3 months after surgery;<br/> assessed with OCT </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1021<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial results were inconsistent (I<sup>2</sup> = 87%). Results ranged from ‐30.9 microns in favour of NSAIDs plus steroids to +7.44 microns in favour of steroids alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In general, no major adverse effects were noted. The main consistent observation was burning or stinging sensation with use of NSAID drops. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MO at 3 months after cataract surgery, clinically symptomatic,<br/> assessed with OCT </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000 (42 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40 (CI 0.32 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3638</p> <p>(21 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA at 3 months after surgery;<br/> assessed with logMAR<br/> scale from: ‐1.3 to 1.3 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1158<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial results were inconsistent (I<sup>2</sup> = 70%), but all except one study found differences less than 0.1 logMAR, i.e. clinically indistinguishable from no difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BCVA</b> : best corrected visual acuity; <b>CI:</b> confidence interval; <b>MO</b> : macular oedema; <b>NSAID</b> : non‐steroidal anti‐inflammatory drug; <b>OCT</b> : optical coherence tomography; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 level for risk of bias: studies at unclear or high risk of bias.<br/> <sup>2</sup> Downgraded 1 level for indirectness: extent of visual loss not always clearly defined.<br/> <sup>3</sup> Downgraded 2 levels for imprecision: Only 2 events.<br/> <sup>4</sup> Downgraded 1 level for publication bias: asymmetric funnel plot suggestive of publication bias. </p> <p><sup>5</sup> We considered downgrading an additional 1 level for indirectness as the MO was not always OCT‐verified and it was not always clear if the MO was clinically symptomatic. However, we did not do so partly because the size of the effect was quite strong. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006683-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NSAIDS compared with steroids for the prevention of macular oedema after cataract surgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NSAID</b> s<b>compared with steroids for the prevention of macular oedema after cataract surgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people having cataract surgery<br/> <b>Setting:</b> eye hospital<br/> <b>Intervention:</b> NSAIDs<br/> <b>Comparison:</b> steroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision outcome due to MO at 3 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision outcome due to MO at 12 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life at 3 months after surgery</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central retinal thickness at 3 months after surgery;<br/> assessed with OCT </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean central retinal thickness at 3 months after surgery was 228 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 22.64 microns lower<br/> (38.86 lower to 6.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>488<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study had 2 unspecified complications in 142 participants, 2 studies reported that no adverse events were noted in either group, 1 study (55 people) mentioned 15 mild adverse effects but unclear if related to treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MO at 3 months after cataract surgery; clinically symptomatic<br/> assessed with OCT </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> <p>(23 to 53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.27 (0.18 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA at 3 months after surgery;<br/> assessed with logMAR<br/> scale from: ‐1.3 to 1.3 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial results were inconsistent (I<sup>2</sup> = 84%), but all studies found differences less than 0.1 logMAR, </p> <p>i.e. clinically indistinguishable from no difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BCVA</b> : best corrected visual acuity; <b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>MO</b> : macular oedema; <b>NSAID</b> : non‐steroidal anti‐inflammatory drug; <b>OCT</b> : optical coherence tomography; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 level for risk of bias: studies at unclear or high risk of bias.<br/> <sup>2</sup> Downgraded 1 level for publication bias: asymmetric funnel plot suggestive of publication bias. </p> <p><sup>3</sup> We considered downgrading 1 level for indirectness as the MO was not always OCT‐verified and not always clear if it was clinically symptomatic however we did not do so, partly because the effect was strong.<br/> <sup>4</sup> Downgraded 1 level for imprecision: confidence intervals include clinically unimportant effect.<br/> <sup>5</sup> Downgraded 1 level for inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006683-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006683-sec-0023"></div> <section id="CD006683-sec-0024"> <h3 class="title" id="CD006683-sec-0024">Description of the condition</h3> <p>Cataract refers to the clouding of the natural crystalline lens of the eye. It is the leading cause of avoidable visual impairment and blindness in the world. The World Health Organization (WHO) estimates that unoperated cataract alone accounts for 33% of visual impairment, an estimated 94 million cases worldwide (<a href="./references#CD006683-bbs2-0083" title="PascoliniD , MariottiSP . Global estimates of visual impairment: 2010. British Journal of Ophthalmology2012;96(5):614‐8. ">Pascolini 2012</a>). In many parts of the world, particularly higher‐income countries, availability of cataract surgery at a relatively early stage of visual impairment in the disease process has led to this procedure being one of the most commonly performed surgical procedures worldwide. </p> <p>Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula) which may present following cataract surgery with lens implantation (pseudophakic macular oedema) or without (aphakic macular oedema) and may give rise to poor visual outcome with reduced visual acuity and distortion of the central vision. The diagnosis of this condition is made both clinically using slit lamp biomicroscopic examination of the macula and with the aid of fundus fluorescein angiography or optical coherence tomography (OCT) (<a href="./references#CD006683-bbs2-0062" title="ChoiJ , BuzneySM , WeiterJJ . Cystoid macular edema: current modes of therapy. International Ophthalmology Clinics2005;45(4):143‐51. ">Choi 2005</a>). </p> <p>The incidence of MO varies with type of surgery, intraoperative complications and pre‐existing risk factors. Reported risk of MO varies between 0.9% and 5% for modern uncomplicated phacoemulsification cataract surgery (<a href="./references#CD006683-bbs2-0090" title="SpaideRF , YannuzziLA , SiscoLJ . Chronic cystoid macular edema and predictors of visual acuity. Ophthalmic Surgery1993;24(4):262‐7. ">Spaide 1993</a>), but can be as high as 10% in the presence of surgical complications such as vitreous loss (<a href="./references#CD006683-bbs2-0060" title="BlomquistPH , RugwaniRM . Visual outcomes after vitreous loss during cataract surgery performed by residents. Journal of Cataract and Refractive Surgery2002;28(5):847‐52. ">Blomquist 2002</a>). Vision is not always affected, and the incidence of MO with decrease in visual acuity is reported at 1% (<a href="./references#CD006683-bbs2-0057" title="AhmedI , EverettA . Cystoid macular edema. In: YanoffM , DukerJS editor(s). Ophthalmology. 4th Edition. Mosby, 2013:Section 6, page 34. ">Ahmed 2013</a>), and is associated with increasing retinal thickness (<a href="./references#CD006683-bbs2-0070" title="HeeMR , PuliafitoCA , WongD , DukerJS , ReichelE , RutledgeB , et al. Quantitative assessment of macular edema with optical coherence tomography. Acta Ophthalmologica1995;113(8):1019‐29. ">Hee 1995</a>). A multicentre audit of 55,567 cataract operations in the UK's National Health Service (NHS) showed a risk of 1.62%, at a median postoperative review time of 31 days (<a href="./references#CD006683-bbs2-0074" title="JaycockP , JohnstonRL , TaylorH , AdamsM , ToleDM , GallowayP , et al. The national cataract dataset electronic multi‐centre audit of 55,567 operations: updating the benchmark standards of care in the UK and internationally. Eye2009;23(1):38‐49. ">Jaycock 2009</a>). This was based on surgeons' reports rather than systematic examination of the macula and was defined as poor visual outcome attributed to MO. </p> <p>Other risk factors for MO include ocular inflammatory diseases such as uveitis, retinal ischaemic conditions such as central and branch retinal vein conditions, retinal vascular diseases and dystrophies, for example retinitis pigmentosa and retinal telangiectasia, as well as degenerative causes such as age related macular degeneration and diabetic retinopathy while the use of topical prostaglandin analogue therapy in glaucoma remains a theoretical risk (<a href="./references#CD006683-bbs2-0082" title="NelsonMS , MartidisA . Managing cystoid macular edema after cataract surgery. Current Opinion in Ophthalmology2003;14(1):39‐43. ">Nelson 2003</a>). The use of topical adrenaline 2% (epinephrine) in aphakic patients has also been described to be associated with macular oedema. Other factors may include cerebrovascular and cardiovascular disease (<a href="./references#CD006683-bbs2-0073" title="JainR , StevensJD , BunceCV , GarrettC , HykinPG . Ischaemic heart disease may predispose to pseudophakic cystoid macular oedema. Eye2001;15(Pt 1):34‐8. ">Jain 2001</a>) but the pathogenesis is unclear. </p> <p>MO is often self‐limiting with spontaneous resolution (<a href="./references#CD006683-bbs2-0057" title="AhmedI , EverettA . Cystoid macular edema. In: YanoffM , DukerJS editor(s). Ophthalmology. 4th Edition. Mosby, 2013:Section 6, page 34. ">Ahmed 2013</a>). The small proportion of patients with chronic persistent MO may be difficult to treat (<a href="./references#CD006683-bbs2-0095" title="YannuzziLA , GuyerDR , GreenWR . The Retina Atlas. 1st Edition. Elsevier Health Sciences, 1995. ">Yannuzzi 1995</a>), and they may experience permanent reduction in vision from atrophy of the photoreceptor layer of the retina (<a href="./references#CD006683-bbs2-0057" title="AhmedI , EverettA . Cystoid macular edema. In: YanoffM , DukerJS editor(s). Ophthalmology. 4th Edition. Mosby, 2013:Section 6, page 34. ">Ahmed 2013</a>). Chronic oedema may lead to the formation of cystic spaces in the retina, termed 'cystoid macular oedema' (CMO). </p> </section> <section id="CD006683-sec-0025"> <h3 class="title" id="CD006683-sec-0025">Description of the intervention</h3> <p>The intervention is the topical use of non‐steroidal anti‐inflammatory drugs (NSAIDs), in this case, eyedrops, in addition to topical steroid eyedrops after cataract surgery. They may also be used preoperatively, primarily to reduce the risk of pupil constriction during surgery, but this may potentially also reduce the risk of MO. Non‐steroidal anti‐inflammatory agents are a group of drugs which are in common use orally as over‐the‐counter treatments for the reduction of pain, redness and swelling associated with systemic inflammation. Some of these are also available in eyedrop form as prescription medicines for the reduction of ocular inflammation. </p> <p>The comparative intervention is the use of topical steroids on the eye after cataract surgery, which is current standard therapy, and may in itself reduce the risk of MO. Steroids are a group of prescription‐only drugs which are used systemically to suppress the symptoms, signs and sequelae of inflammation. They are also used in their topical eyedrop form for the reduction of ocular inflammation. </p> <p>In the last decade or so, several clinical trials have examined the use of topical NSAIDs in the treatment and prevention of postoperative inflammation and pseudophakic macular oedema, without the adverse effects of topical corticosteroids (<a href="./references#CD006683-bbs2-0059" title="BallonzoliL , BourcierT . Ocular side effects of steroids and other immunosuppressive agents. Therapie2010;65(2):115‐20. ">Ballonzoli 2010</a>; <a href="./references#CD006683-bbs2-0061" title="CarnahanMC , GoldsteinDA . Ocular complications of topical, peri‐ocular, and systemic corticosteroids. Current Opinion in Ophthalmology2000;11(6):478‐83. ">Carnahan 2000</a>; <a href="./references#CD006683-bbs2-0071" title="HeierJ , CheethamJK , DegryseR , DirksMS , CaldwellDR , SilverstoneDE , et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle‐controlled clinical trial. American Journal of Ophthalmology1999;127(3):253‐9. ">Heier 1999</a>; <a href="./references#CD006683-bbs2-0084" title="PolanskyJR . Side effects of topical therapy with anti‐inflammatory steroids. Current Opinion in Ophthalmology1992;3(2):259‐72. ">Polanski 1992</a>; <a href="./references#CD006683-bbs2-0089" title="SolomonKD , CheethamJK , DeGryseR , BrintSF , RosenthalA . Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology2001;108(2):331‐7. ">Solomon 2001</a>). NSAIDs such as ketorolac and indomethacin are cyclo‐oxygenase inhibitors which suppress breakdown of the blood‐aqueous barrier that may occur in the early postoperative period (<a href="./references#CD006683-bbs2-0065" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479‐86. ">Flach 1987</a>; <a href="./references#CD006683-bbs2-0066" title="FlachAJ , KraffMC , SandersDR , TanenbaumL . The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood‐aqueous barrier. Archives of Ophthalmology1988;106(4):480‐3. ">Flach 1988</a>; <a href="./references#CD006683-bbs2-0081" title="MiyakeK . Indomethacin in the treatment of postoperative cystoid macular edema. Survey of Ophthalmology1984;28(Suppl):554‐68. ">Miyake 1984</a>; <a href="./references#CD006683-bbs2-0087" title="SandersDR , KraffM . Steroidal and nonsteroidal anti‐inflammatory agents. Effect on postsurgical inflammation and blood‐aqueous humor barrier breakdown. Archives of Ophthalmology1984;102(10):1453‐6. ">Sanders 1984</a>). </p> <p><a href="./references#CD006683-bbs2-0073" title="JainR , StevensJD , BunceCV , GarrettC , HykinPG . Ischaemic heart disease may predispose to pseudophakic cystoid macular oedema. Eye2001;15(Pt 1):34‐8. ">Jain 2001</a> recommended the use of prophylactic NSAIDs in patients with predisposing factors to developing postsurgical MO, irrespective of cause. Other clinical studies suggest that topical NSAIDs may be more effective than topical steroids in re‐establishing the blood‐aqueous barrier postoperatively, suggesting an important role in MO prevention (<a href="./references#CD006683-bbs2-0067" title="FlachAJ , JaffeNS , AkersWA . The effect of ketorolac tromethamine in reducing postoperative inflammation: double‐mask parallel comparison with dexamethasone. Annals of Ophthalmology1989;21(11):407‐11. ">Flach 1989</a>; <a href="./references#CD006683-bbs2-0079" title="KraffMC , SandersDR , McGuiganL , RaananMG . Inhibition of blood‐aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Archives of Ophthalmology1990;108(3):380‐3. ">Kraff 1990</a>; <a href="./references#CD006683-bbs2-0091" title="UrsellPG , SpaltonDJ , WhitcupSM , NussenblattRB . Cystoid macular edema after phacoemulsification: relationship to blood‐aqueous barrier damage and visual acuity. Journal of Cataract and Refractive Surgery1999;25(11):1492‐7. ">Ursell 1999</a>). </p> <p>The meta‐analysis conducted in <a href="./references#CD006683-bbs2-0086" title="RossettiL , ChaudhuriJ , DickersinK . Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta‐analysis. Ophthalmology1998;105(3):397‐405. ">Rossetti 1998</a> of the use of NSAIDs suggested possible beneficial effects of NSAIDs for both the prophylaxis and treatment of MO, but concluded that the overall quality of the evidence was insufficient to justify recommendation of its widespread use in prophylaxis. A Cochrane Review on treatment of MO following cataract surgery, found that two out of seven included randomised controlled trials (RCTs) showed a beneficial effect of NSAIDs on chronic MO (<a href="./references#CD006683-bbs2-0088" title="SivaprasadS , BunceC , PatelN . Non‐steroidal anti‐inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004239.pub2] ">Sivaprasad 2004</a>), although problems with trial quality and heterogeneity prevented valid meta‐analysis. </p> <p>A recent randomised, placebo‐controlled trial looking at the adjunctive effect of topical NSAIDs in addition to intravitreal steroids (triamcinolone) and intravitreal anti‐vascular endothelial growth factor (bevacizumab) in chronic MO, found a statistically significant improvement with the use of topical nepafenac in reduction of retinal thickness and improvement in visual acuity at 16 weeks (<a href="./references#CD006683-bbs2-0093" title="WarrenK , BahraniH , FoxJE . NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina2010;30(2):260‐6. ">Warren 2010</a>). NSAIDs have also been used with good tolerance and efficacy, as an alternate treatment for patients with MO of mixed origin who are steroid responders, and therefore cannot be treated with steroids (<a href="./references#CD006683-bbs2-0092" title="WarrenKA , FoxJE . Topical nepenafac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina2008;28(10):1427‐34. ">Warren 2008</a>). </p> </section> <section id="CD006683-sec-0026"> <h3 class="title" id="CD006683-sec-0026">How the intervention might work</h3> <p>NSAIDs are cyclo‐oxygenase inhibitors and may work by reducing the production of pro‐inflammatory prostaglandins. Inflammation within tissue is caused by the production of pro‐inflammatory products by several pathways. NSAIDs act to suppress the cyclo‐oxygenase pathway of inflammation, inhibiting production of prostaglandins (<a href="./references#CD006683-bbs2-0064" title="EisenachJC , CurryR , TongC , HouleTT , YakshTL . Effects of intrathecal ketorolac on human experimental pain. Anesthesiology2010;112(5):1216‐24. ">Eisenach 2010</a>). </p> </section> <section id="CD006683-sec-0027"> <h3 class="title" id="CD006683-sec-0027">Why it is important to do this review</h3> <p>As cataract surgery is the second most commonly performed operation worldwide, and MO occurs in between 1% and 10% of all cataract surgeries (depending on risk and complications) and leads to poor visual outcome, there is a significant volume of visual morbidity which can be potentially prevented if it is found that NSAIDs are effective in its prophylaxis. NSAIDs are relatively inexpensive, easily obtainable and carry the potential to significantly improve the outcome of cataract surgery worldwide. </p> <p>Despite some evidence in favour of the beneficial effects of NSAIDs in MO, uncertainty remains about whether it has significant benefit in the prevention of MO when used perioperatively in addition to steroids. A recent editorial posed the question as to how prescribing NSAIDs for routine cataract surgery became so popular in the USA without compelling evidence of a visual benefit to patients (<a href="./references#CD006683-bbs2-0078" title="KimSJ , PatelSN , SternbergPJr . Routine use of nonsteroidal anti‐inflammatory drugs with corticosteroids in cataract surgery: Beneficial or redundant?. Ophthalmology2016;123(3):444‐6. ">Kim 2016a</a>). This uncertainty is reflected in widespread variation in clinical practice. For example, NSAIDs are much less frequently used in the UK for this indication. This review attempts either to resolve the persisting clinical uncertainty or to identify the need for further research to achieve such resolution. </p> <p>This review is confined to addressing the use of NSAIDs in the prophylaxis of MO. A separate Cochrane Review on treatment of established cystoid macular oedema (CMO) has already been published (<a href="./references#CD006683-bbs2-0088" title="SivaprasadS , BunceC , PatelN . Non‐steroidal anti‐inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004239.pub2] ">Sivaprasad 2004</a>), but the effectiveness of NSAIDs in treatment remains uncertain. MO can lead to permanent structural damage in the central retina, therefore a prevention strategy may be more effective than treatment after the damage has been done. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006683-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006683-sec-0028"></div> <p>The aim of this review is to answer the question: is there evidence to support the prophylactic use of topical NSAIDs either in addition to, or instead of, topical steroids postoperatively to reduce the incidence of macular oedema (MO) and associated visual morbidity. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006683-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006683-sec-0029"></div> <section id="CD006683-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006683-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs) in this review. We excluded within‐person studies i.e. studies where eyes are randomly allocated to the intervention and comparator due to the possibility that the effect of non‐steroidal anti‐inflammatory drugs (NSAIDs) in one eye may affect the outcome in the other. </p> </section> <section id="CD006683-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included trials in which adult participants had undergone standard surgery for age‐related cataract. We included participants irrespective of their baseline risk of MO, in particular, we included people with diabetes and uveitis. </p> </section> <section id="CD006683-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The primary comparison of this review was topical NSAIDs in addition to topical steroids versus topical steroids alone in cataract surgery. Surgery can include extracapsular cataract extraction (ECCE; large incision with sutures), manual small incision cataract surgery (MSICS; small incision without sutures), phacoemulsification cataract surgery (mechanised small incision extracapsular extraction) and intracapsular cataract extraction (ICCE; planned and unplanned intracapsular procedures). </p> <p>We included trials of preoperative and/or postoperative topical NSAIDs in conjunction with postoperative topical steroids. The comparator was postoperative topical steroids alone. </p> <p>A secondary comparison was preoperative and/or postoperative topical NSAIDs alone versus topical postoperative steroids alone. </p> <p>We included studies irrespective of whether incident MO was subsequently treated.</p> </section> <section id="CD006683-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD006683-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006683-list-0001"> <li> <p>The proportion of people with a poor vision outcome due to MO in the study eye at three months after surgery. </p> </li> </ul> </p> <p>We defined poor vision outcome as best corrected visual acuity (BCVA) not improving to 6/9 or better (or equivalent with other notations of vision) attributed to a diagnosis of MO (detected clinically, angiographically or on optical coherence tomography (OCT)). This included participants who developed MO and required and received treatment. </p> <p>Our primary outcome was measured at three months after surgery, which we took as any observation between one month and six months after surgery. We also examined poor visual outcome due to MO at 12 months after surgery, which we took as any observation between six and 18 months after surgery. </p> </section> <section id="CD006683-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006683-list-0002"> <li> <p>Any quality of life or patient satisfaction measure relating to the patient's experience of surgery on the study eye., at three months and 12 months after surgery </p> </li> <li> <p>Change in central retinal thickness from preoperative assessment in the study eye, at three months and 12 months after surgery, as measured by OCT scan. If change in central retinal thickness was not available we used the final value. </p> </li> </ul> </p> <section id="CD006683-sec-0037"> <h6 class="title">Adverse effects</h6> <p>We looked at known harms of NSAIDs including respiratory effects and gastrointestinal disturbance, in addition to intolerance of medication and allergic reactions. We recorded any other harms such as liver toxicity, as has been reported with some NSAIDs. </p> </section> <section id="CD006683-sec-0038"> <h6 class="title">Resource use and costs</h6> <p>In our protocol (<a href="./references#CD006683-bbs2-0096" title="AbeysiriP , WormaldR , BunceC . Prophylactic non‐steroidal anti‐inflammatory agents for the prevention of cystoid macular oedema after cataract surgery. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD006683.pub2] ">Abeysiri 2011</a>) we planned to look at economic evaluations of the cost‐effectiveness and cost per quality‐adjusted life year (QALY)/disability‐adjusted life year (DALY) modelling. We amended this to look at resource use and costs more generally. </p> </section> <section id="CD006683-sec-0039"> <h6 class="title">Additional outcomes (National Institute for Health and Care Excellence (NICE))</h6> <p>We collected data on the following additional outcomes as part of our collaboration with NICE. </p> <p> <ul id="CD006683-list-0003"> <li> <p>Macular oedema (MO) (clinically symptomatic, OCT‐verified).</p> </li> <li> <p>Inflammation.</p> </li> <li> <p>BCVA.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD006683-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006683-sec-0041"> <h4 class="title">Electronic searches</h4> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 8), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to September 2016), Embase (January 1980 to September 2016), Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to September 2016), the ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2 September 2016. </p> <p>See: Appendices for details of search strategies for CENTRAL (<a href="./appendices#CD006683-sec-0112">Appendix 1</a>), MEDLINE (<a href="./appendices#CD006683-sec-0113">Appendix 2</a>), Embase (<a href="./appendices#CD006683-sec-0114">Appendix 3</a>), LILACS (<a href="./appendices#CD006683-sec-0115">Appendix 4</a>), ISRCTN (<a href="./appendices#CD006683-sec-0116">Appendix 5</a>), ClinicalTrials.gov (<a href="./appendices#CD006683-sec-0117">Appendix 6</a>), and the ICTRP. </p> </section> <section id="CD006683-sec-0042"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of the studies included in the review. We used the Science Citation Index to find studies that have cited the individual trials. We did not handsearch conference proceedings or journals specifically for the review. </p> </section> </section> <section id="CD006683-sec-0043"> <h3 class="title" id="CD006683-sec-0043">Data collection and analysis</h3> <section id="CD006683-sec-0044"> <h4 class="title">Selection of studies</h4> <p>Three review authors (CL, BL, DL) screened the titles and abstracts resulting from the searches independently. We obtained full copies of the potentially relevant trials. Three review authors (CL, BL, DL) independently assessed full copies for inclusion according to the '<a href="#CD006683-sec-0030">Criteria for considering studies for this review</a>.' We resolved disagreements by discussion. </p> <p>We listed all excluded studies and provided a brief justification for exclusion (See <a href="./references#CD006683-sec-0130" title="">Characteristics of excluded studies</a>). </p> </section> <section id="CD006683-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (JE, CL, DL, BL) independently extracted data using a pre‐piloted data extraction template in Covidence (<a href="./references#CD006683-bbs2-0063" title="Veritas Health Innovation. Covidence systematic review software. Melbourne: Veritas Health Innovation, (accessed prior to 30 September 2016). ">Covidence 2016</a>). A fifth review author (CB) generated a random sample of 20% of studies and checked data input for these. We resolved discrepancies by discussion. </p> <p>We collected the following information on study characteristics (<a href="./appendices#CD006683-sec-0119">Appendix 8</a>). </p> <p> <ul id="CD006683-list-0004"> <li> <p>Study design: parallel group RCT, one or both eyes included and/or reported.</p> </li> <li> <p>Participants: country, total number of participants, age, sex, inclusion and exclusion criteria. </p> </li> <li> <p>Intervention and comparator details: including number randomised to each.</p> </li> <li> <p>Primary and secondary outcomes as measured and reported in the trials, adverse events, methods of measurement (e.g. which chart is used for visual acuity assessment, which OCT scanner was used). </p> </li> <li> <p>Length of follow‐up.</p> </li> <li> <p>Date study conducted.</p> </li> <li> <p>Funding and conflicts of interest reported.</p> </li> <li> <p>Trial registration number.</p> </li> </ul> </p> <p>We collected data on our predefined outcomes separately for intervention and comparator groups. For multi‐arm studies we planned to use data relevant to our intervention and comparator groups. If two groups contain relevant data (for example, if pre/postoperative application of NSAIDs) we combined groups using the RevMan calculator (<a href="./references#CD006683-bbs2-0085" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>As far as possible, we extracted data for an intention‐to‐treat (ITT) analysis. We contacted trial investigators as needed. Data were imported directly from Covidence into Review Manager 5 by JE (<a href="./references#CD006683-bbs2-0085" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and checked by the other review authors (CL, DL, BL). CB then conducted a final random assessment. </p> </section> <section id="CD006683-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used Cochrane's 'Risk of bias' tool for assessing risk of bias in each included study. Four review authors (JE, CL, DL, BL) independently assessed risk of bias according to methods set out in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006683-bbs2-0072" title="HigginsJP , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We followed the specific rules as set out in <a href="#CD006683-tbl-0003">Table 1</a> and resolved disagreements by discussion. </p> <div class="table" id="CD006683-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">'Risk of bias' assessment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Domain</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unclear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer‐generated list, random table, other method of generating random list.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported how list was generated. Trial may be described as “randomised” but with no further details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alternate allocation, date of birth, records (these RCTs should be excluded).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central centre (web/telephone access), sealed opaque envelopes.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported how allocation administered. Trial may be described as “randomised” but with no further details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator involved in treatment allocation or treatment allocation clearly not masked. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of participants and personnel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearly stated that participants and personnel not aware of which treatment received.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Described as “double‐blind” with no information on who was masked.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label or no information on masking. We assume that in absence of reporting on this outcome, patients and personnel were not masked. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of outcome assessors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearly stated that outcome assessors were masked.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Described as “double‐blind” with no information on who was masked.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label or no information on masking. We assume that in absence of reporting on this outcome, assessors were not masked. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data less than 20% (i.e. more than 80% follow‐up) and equal follow‐up in both groups and no obvious reason why loss to follow‐up should be related to outcome. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up not reported or missing data &gt; 20% (i.e. follow‐up &lt; 80%) but follow‐up equal in both groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up different in each group and/or related to outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective outcome reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All outcomes in protocol and/or trial registry entry are reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No access to protocol or trial registry entry.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes in protocol and/or trial registry entry selectively reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other sources of bias</p> <p>Note: we did not identify any important sources of other bias so this domain is omitted from the risk of bias tables. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No other source of bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial stopped early due to poor recruitment.</p> <p>Baseline imbalance, but not clear that it is important.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial stopped early because of outcome.</p> <p>Important baseline imbalance that might have an effect on the results.</p> </td> </tr> </tbody> </table> </div> <p>We contacted trial investigators for <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> for clarification of random allocation. </p> </section> <section id="CD006683-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio for outcome measures reported as dichotomous data (for example, poor visual acuity attributed to MO within three months). We calculated the mean difference for measures of retinal thickness. We planned to analyse ordinal outcome data as dichotomous data if an established defensible cut‐off point is available, such as quality of life measures. We did not plan to meta‐analyse adverse effects. </p> </section> <section id="CD006683-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>Trials included may randomise one or both eyes to the intervention or comparator. If both eyes were allocated to the same treatment, we planned to analyse as 'clustered data' if data were available. In the event four trials included data on both eyes, but this was generally a small proportion of the total participants. We have analysed as reported. We excluded studies which allocated different eyes to different treatments as there may be a confounding cross‐over effect due to systemic absorption. </p> </section> <section id="CD006683-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>We assessed all included trials for number of participants excluded or lost to follow‐up. We documented reasons for loss to follow‐up by treatment group, if reported. We aimed to do an ITT analysis for included trials using imputed data; if computed by the trialists we did not plan to impute missing data on their behalf. </p> </section> <section id="CD006683-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where heterogeneity was observed between individual study results we did not combine studies but present a tabulated summary of results. We did not rely on statistical significance of a Chi<sup>2</sup> test to indicate heterogeneity but examined the forest plot of the study results and the overall characteristics of the studies. We looked at the consistency between studies by examining the I<sup>2</sup> statistic value. We considered I<sup>2</sup> values over 50% to indicate substantial inconsistency, but we also considered the direction of effects. </p> </section> <section id="CD006683-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>We considered selective outcome reporting under the risk of bias assessment (<a href="#CD006683-tbl-0003">Table 1</a>). We planned to look at funnel plots and consider tests for asymmetry for bias assessment in the event of 10 or more trials contributing data to a meta‐analysis. </p> </section> <section id="CD006683-sec-0052"> <h4 class="title">Data synthesis</h4> <p>We aimed to use a random‐effects model provided we did not detect substantial inconsistency between individual study results. If there were fewer than three trials in a comparison we planned to use the fixed‐effect model. Where heterogeneity was observed between studies (see <a href="#CD006683-sec-0050">Assessment of heterogeneity</a>) we did not combine studies but presented a narrative summary of results. </p> <section id="CD006683-sec-0053"> <h5 class="title">'Summary of findings' table</h5> <p>We prepared a 'Summary of findings' table presenting relative and absolute risks. We graded the overall certainty of the evidence for each outcome using the GRADE classification (<a href="./references#CD006683-bbs2-0058" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We considered the following: risk of bias of included studies, precision of the effect estimate, consistency of effects between studies, directness of the outcome measure and publication bias. JE did the assessment and this was checked by other authors. We included the following outcomes in the 'Summary of findings' tables. </p> <p> <ol id="CD006683-list-0005"> <li> <p>Poor vision outcome due to MO at three months after surgery.</p> </li> <li> <p>Poor vision outcome due to MO at 12 months after surgery.</p> </li> <li> <p>Quality of life at three months after surgery.</p> </li> <li> <p>Central retinal thickness at three months after surgery.</p> </li> <li> <p>Adverse effects.</p> </li> <li> <p>MO (clinically symptomatic, OCT‐verified) at three months after surgery</p> </li> <li> <p>BCVA at three months after surgery.</p> </li> </ol> </p> </section> </section> <section id="CD006683-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct a subgroup analysis on the primary outcome comparing the effect of treatment on people with higher baseline risk of MO (diabetes/uveitis) with people with lower risk of MO (no diabetes/uveitis), but we did not do them as planned as there were not enough data on the primary outcome. </p> </section> <section id="CD006683-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform three sensitivity analyses on the primary outcome, but we did not do them as planned as there were not enough data on the primary outcome. </p> <p> <ul id="CD006683-list-0006"> <li> <p>Excluding studies at high risk of bias in one or more domains.</p> </li> <li> <p>Excluding industry‐funded studies.</p> </li> <li> <p>Comparing fixed‐effect and random‐effects models (if three or more trials).</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006683-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006683-sec-0056"></div> <section id="CD006683-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD006683-sec-0058"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded a total of 928 references (<a href="#CD006683-fig-0001">Figure 1</a>). The Cochrane Information Specialist removed 337 duplicate records and we screened the remaining 591 reports. We rejected 526 records after reading the abstracts and obtained the full‐text reports of 65 references for further assessment. We identified 43 reports of 34 studies which met the inclusion criteria (see <a href="./references#CD006683-sec-0129" title="">Characteristics of included studies</a> for details), and excluded 18 reports of 18 studies (see <a href="https://archie.cochrane.org/sections/documents/view?version=z1607062152024264433528577269096%26format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES" target="_blank">Characteristics of excluded studies</a> for details). One unpublished trial is currently awaiting assessment (<a href="./references#CD006683-bbs2-0053" title="CTRI/2009/091/001078 . Randomised, triple blinded, placebo controlled, clinical trial to compare the effect of Ketorolac tromethamine 0.4% in prophylactically preventing cystoid macula edema following cataract surgery. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1207 (accessed 5 October 2016). ">CTRI/2009/091/001078</a>). We identified three ongoing studies (<a href="./references#CD006683-bbs2-0054" title="NCT01694212 . Effect of perioperative topical diclofenac on intraocular inflammation after cataract surgery and the incidence of postoperative macular edema in patients with diabetic retinopathy. clinicaltrials.gov/ct2/show/NCT01694212 (accessed 5 October 2016). ">NCT01694212</a>; <a href="./references#CD006683-bbs2-0055" title="NCT01774474 . PRevention of Macular EDema after cataract surgery (PREMED). clinicaltrials.gov/ct2/show/NCT01774474 (accessed 5 October 2016). ">NCT01774474</a>; <a href="./references#CD006683-bbs2-0056" title="NCT02646072 . The effect of preoperative topical ketorolac 0.45% on aqueous cytokine levels and macular thickness in diabetic and non diabetic patients undergoing cataract surgery. clinicaltrials.gov/ct2/show/NCT02646072 (accessed 5 October 2016). ">NCT02646072</a>). </p> <div class="figure" id="CD006683-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006683-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006683-sec-0059"> <h4 class="title">Included studies</h4> <p>We have summarised the characteristics of the 34 included studies below. Details for individual studies can be found in the <a href="./references#CD006683-sec-0129" title="">Characteristics of included studies</a>. The information is also summarised in <a href="#CD006683-tbl-0004">Table 2</a>; <a href="#CD006683-tbl-0005">Table 3</a>; <a href="#CD006683-tbl-0006">Table 4</a>; <a href="#CD006683-tbl-0007">Table 5</a>; <a href="#CD006683-tbl-0008">Table 6</a> </p> <div class="table" id="CD006683-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Open‐label</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funding sources</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Declaration of interest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial registration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abstract only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00335439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01395069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry/Non‐Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00494494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00782717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada (8 sites) and Germany (2 sites)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02084576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00348244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry/Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CoI: conflict of interest</p> </div> </div> <div class="table" id="CD006683-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Participant numbers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people randomised (missing data imputed)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of eyes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of eyes estimated (missing data imputed)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people followed up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people followed up (missing data imputed)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eyes per person enrolled in the trial</b> </p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 eyes of 98 people</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 eyes of 70 patients</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 eyes of 210 people</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye; right eye only</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 eyes of 198 people</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*For studies that did not report the number randomised, we have estimated this from the number followed up. For studies that did not report the number followed up, we have estimated this from the numbers randomised. Number of eyes estimated assuming one eye per person, if not clearly stated otherwise. </p> </div> </div> <div class="table" id="CD006683-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Participant characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% female</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% with uveitis</b> </p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 to 92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but low risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"low risk population"</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but people with DR excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 to 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 to 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 to 97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 to 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 to 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 to 86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but people with DR excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 to 87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 to 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but people with DR excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 to 92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DR: diabetic retinopathy</p> </div> </div> <div class="table" id="CD006683-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of cataract surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Steroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo in comparator group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of placebo</b> </p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%, Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sterile saline drops</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1% (combined with tobramycin 0.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1%,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamethasone (with fradiomycin sulfate) followed by fluorometholone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac 0.1%,</p> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone acetate 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE and phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (in combination with neomycin sulfate, polymyxin B sulfate) for 4 days followed by dexamethasone alone for 4 weeks followed by fluorometholone for at least 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorometholone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorometholone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids/NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamethasone 0.1%, fluorometholone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1% (combined with chloramphenicol 0.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flurbiprofen 0.03%</p> <p>Indomethacin 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dextran 70/hypromellose</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%, Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE/ICCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with either chloramphenicol or neomycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> fluorometholone 0.1% and dexamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids given as part of standard care, not specified exactly what</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artifical tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pranoprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ECCE: extracapsular cataract extraction<br/> ICCE: intracapsular cataract extraction<br/> NSAIDs: non‐steroidal anti‐inflammatory drugs </p> </div> </div> <div class="table" id="CD006683-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Poor vision outcome due to MO</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life/patient satisfaction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Central retinal thickness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CMO</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BCVA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Additional outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0005" title="">Analysis 1.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No analysis; only one study reported this</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0006" title="">Analysis 1.2</a>; <a href="./references#CD006683-fig-0012" title="">Analysis 2.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="#CD006683-tbl-0009">Table 7</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0008" title="">Analysis 1.4</a>; <a href="./references#CD006683-fig-0013" title="">Analysis 2.2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0009" title="">Analysis 1.5</a>; <a href="./references#CD006683-fig-0010" title="">Analysis 1.6</a>; <a href="./references#CD006683-fig-0014" title="">Analysis 2.3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0011" title="">Analysis 1.7</a>; <a href="./references#CD006683-fig-0015" title="">Analysis 2.4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0007" title="">Analysis 1.3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT used but CMO not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in total macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COMTOL questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change reported but not possible to calculate SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in total macular volume; change in average macular cube thickness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification (at 5 weeks only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser flare‐cell photometry, mean value of anterior chamber flare (photons/millisecond)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser flare‐cell photometry, mean value of anterior chamber flare reported (photons) but was not possible to calculate SD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "None of the patients developed clinically significant macular oedema associated with vision loss" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only reported CMO associated with vision loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Inflammatory cells greater than 1+ during first week of postoperative visits"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundoscopy and Amsler grid test</p> <p>Quote: "no evidence of clinically significant CME"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No evidence of clinically significant CME was detected in any patient via fundoscopy and the Amsler grid test" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal oedema or Tyndall reaction or conjunctival hyperaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Clinically significant CME" but otherwise not defined, at 2 weeks only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean inflammation score" but was not possible to calculate SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value but could not extract data on SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical examination, unclear if OCT‐verified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anterior chamber flare values, photon count per millisecond</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Inflammatory score" (sum of anterior chamber cells and flare grade"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between 2.5 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT, "clinically apparent" CME otherwise not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in foveal thickness, change in macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unit of measurement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flare (photons/millisec), final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in logMAR BCVA, categorical 3+, 2, 1 lines increase and no change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Obvious CMO confirmed by OCT"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aqueous flare (photons/millisecond)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"&gt;= 30% increase in central subfield macular thickness from baseline"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flare mentioned but data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corrected BCVA loss of more than 5 letters from day 7 postop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 21 to 60, MO = positive angiography and visual acuity &lt;= 20/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using classification***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity but not reported by treatment group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days (3 months mentioned but not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported but no mean/SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with &gt; 10% increase in retinal thickness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography 0 no leakage (CME absent),1 oedema less than perifoveal, 2 mild perifoveal oedema, 3 moderate perifoveal oedema (approx. 1 disc diameter), 4 severe perifoveal oedema plus drop of 1 line of Snellen acuity since second postoperative week defined as "clinically significant" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value (at 30 days only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐confirmed CMO with "visual impairment" (not specified cutpoint)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CME was defined as central retinal<br/> thickness &gt; 250 μm and the presence of intraretinal cystoid space<br/> beneath the foveal, with the diagnosis confirmed by the same retinal<br/> specialist" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean photon count values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐confirmed CMO with visual acuity &lt; 6/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical and OCT‐based</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMO on fluorescein angiography with visual acuity &lt; 6/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography, evidence but not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Slight fluorescein leakage<br/> into the cystic space without enclosing the entire central<br/> fovea or complete fluorescein accumulation in the cystic<br/> space was diagnosed as angiographic CME" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐verified but not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean anterior chamber flare reported in figure but no SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in total macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐verified but not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tyn granule +</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCVA: best corrected visual acuity<br/> CME: cystoid macular oedema (edema)<br/> CMO: cystoid macular oedema<br/> COMTOL: Comparison of Ophthalmic Medications for Tolerability (questionnaire)<br/> MO: macular oedema<br/> OCT: ocular coherence tomography<br/> SD: standard deviation </p> </div> </div> <section id="CD006683-sec-0060"> <h5 class="title">Setting and conduct of Study</h5> <p>See <a href="#CD006683-tbl-0004">Table 2</a>. </p> <p>The studies were conducted in Brazil (<a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>), Canada (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>), China (<a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>; <a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>), Egypt (<a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a>), Germany (<a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>), Greece (<a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a>; <a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a>) , Italy (<a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>), Japan (<a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>; <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>; <a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a>; <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a>; <a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a>), Mexico (<a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a>), South Korea (<a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a>), Sweden (<a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a>), Switzerland (<a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>), Turkey (<a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a>; <a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a>) and the USA (<a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a>; <a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>). </p> <p>They were all parallel group RCTs, i.e. participants were randomly allocated to intervention or comparator. Three of the studies were described as “open‐label” (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>;; <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>). </p> <p>Four studies were funded by industry alone (<a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a>; ; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>; ); seven studies reported only non‐industry funding (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>; <a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a>; <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>); two studies had funding from both industry and non‐industry sources (<a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a>) and the rest of the studies did not report the source of funding. </p> <p>Declarations of interest were not reported in 12 studies; 17 studies reported that they had no conflicts of interest and six studies reported conflicts of interest for one or more investigators (<a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a>; <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>). </p> <p>Six trials were registered on a publicly available database. For three of these trials the registration was probably prospective as the month of registration was the same, or before, the month the study started (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>).Three trials were registered retrospectively (<a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>). </p> <p>Two trials were reported in abstract form only (<a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>). However, we contacted the first authors of <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> and <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> and we received additional information in the form of a poster from <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>. </p> </section> <section id="CD006683-sec-0061"> <h5 class="title">Participants</h5> <p>See <a href="#CD006683-tbl-0005">Table 3</a> and <a href="#CD006683-tbl-0006">Table 4</a>. </p> <p>There were variations in the reporting of recruited and randomised participants. As such it is difficult to establish definitively the total number of people that were randomised in these trials. We estimate that there were 5532 people (5608 eyes) enrolled in these 34 studies and 4476 followed up. (<a href="#CD006683-tbl-0005">Table 3</a>). </p> <p>Five studies did not report the number of people randomised (<a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>; <a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>). For four of these five studies we estimated the number of people in the trial from the number analysed. One study provided no information on the number of participants (<a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a>). </p> <p>For those studies that did not report follow‐up clearly we have assumed the number randomised and number followed up was the same. </p> <p>The majority of the studies (n = 24) enrolled one eye person in the trial, although this was not always clearly described. In six studies the number of eyes/people was not reported in enough detail to be confident how many eyes per person had been enrolled (<a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>), although it is likely that they too largely performed unilateral surgery. </p> <p>Four studies performed bilateral surgery on a subset of patients, and so had more eyes than people in the trial (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>; <a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>). The proportion of people with bilateral surgery was 1% (<a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>), 8% (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>), 11% (<a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>) and 23% (<a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a>). None of the studies adjusted for within‐person correlation. We have analysed the data as reported. </p> <p>For the studies that reported average age, the median average age of participants was 70 years (<a href="#CD006683-tbl-0006">Table 4</a>). Ages ranged from 37 to 100 years. For the studies that reported gender, the median percentage of women was 54%. </p> <p>Fifteen studies reported that they excluded patients with diabetes or diabetic retinopathy, or were a “low risk population”. Nine studies did not report the diabetes status of their participants. Nine studies included people with diabetes and reported the percentage of the participants with diabetes. The percentage with diabetes was 10%/9% (<a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a>; <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a>), 21%/20% (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a>) and 26% (<a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a>). Five studies only included people with diabetes (<a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a>; <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>; <a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>). </p> <p>The majority of studies either excluded people with uveitis (n = 19) or had a “low risk population” (<a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>), or very low proportion with uveitis (1/56 people) (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>). Thirteen studies did not report uveitis and it was not included in the exclusion criteria. </p> </section> <section id="CD006683-sec-0062"> <h5 class="title">Interventions</h5> <p>See <a href="#CD006683-tbl-0007">Table 5</a> </p> <section id="CD006683-sec-0063"> <h6 class="title">Type of surgery</h6> <p>Twenty‐four of the 34 studies reported that only phacoemulsification was performed for cataract extraction (<a href="#CD006683-tbl-0007">Table 5</a>). In one study both extracapsular cataract extraction (ECCE) and phacoemulsification were performed (<a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>). Four studies reported that they performed ECCE (<a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>; <a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a>), two studies performed ICCE (<a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>) and one study performed a mixture of ECCE/intracapsular cataract extraction (ICCE) (<a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>). In two studies that were reported in abstract form only there was no information on type of surgery but we have assumed that they used phacoemulsification because of the date published and location of the study (<a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>). </p> </section> <section id="CD006683-sec-0064"> <h6 class="title">Comparison</h6> <p>Twenty‐eight of the 34 studies compared non‐steroidal anti‐inflammatory drugs (NSAIDs) with steroids versus steroids. In 14 of these 28 studies, a placebo (for the NSAIDs) was used in the comparator group. This placebo was not specified in two trials (<a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>;); was artificial tears in five trials (<a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>; <a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a>); a vehicle in six studies (<a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>); and sterile saline drops in <a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>. . </p> <p>Six of the 34 studies compared NSAIDs (on their own) with steroids (<a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>; <a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a>; <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>; <a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a>; <a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a>; <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a>). Only one of these studies used a placebo in the steroid group; the contents of this placebo were not specified. (<a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a>). </p> </section> <section id="CD006683-sec-0065"> <h6 class="title">NSAIDs</h6> <p>The most frequently used NSAID was ketorolac (11 studies) followed by diclofenac (9 studies), nepafenac (7 studies), indomethacin (5 studies), bromfenac (4 studies), pranoprofen (1 study) and flurbiprofen (1 study). Four studies had two different NSAID groups ‐ ketorolac and nepafenac (<a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>), ketorolac and bromfenac (<a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a>) and flurbiprofen and indomethacin (<a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>). We combined these groups for the analysis. </p> <p>The ketorolac concentration was either 0.4% or 0.5%. Diclofenac was largely used at a concentration of 0.1% (7 studies) but also used at 1% in <a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> and concentration was not specified in one study (; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>). Nepafenac was used at 0.1% in six studies and 1% in one study (<a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>). Indomethacin 1% was used in three studies (<a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>), 0.1% in <a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> while the concentration used was not specified in <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>. Bromfenac 0.1% was used in <a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a>, <a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> and <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>; it was not specified in <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>. Flubiprofen was used at 0.03% (<a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>). Pranopfen concentration was not specified (<a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>). </p> </section> <section id="CD006683-sec-0066"> <h6 class="title">Steroids</h6> <p>Prednisolone was used in 13 studies, usually at 1%.</p> <p>Dexamethasone was used in 15 studies, at a concentration of 0.1% in eight studies and 1% in one study (<a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a>). The concentration used was not specified in 6 studies. It was combined with tobramycin in four studies (<a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a>; <a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>; <a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>) and other antibiotics (<a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>). </p> <p>Betamethasone was used at 0.1% in two studies (<a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>; <a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a>) and not specified in one study (<a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>). </p> <p>Fluorometholone 0.1% was used as the sole topical corticosteroid therapy in three studies (<a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a>; <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>) and used as part of a tapering regimen in one study (<a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>). </p> <p>The type of steroids used in <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> were not specified. </p> </section> <section id="CD006683-sec-0067"> <h6 class="title">Other medications</h6> <p>Most studies reported the use of additional antibiotics. See <a href="./references#CD006683-sec-0129" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD006683-sec-0068"> <h5 class="title">Outcomes</h5> <p>Maximum follow‐up ranged from one month (8 studies) to 12 months postoperatively (<a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>) (<a href="#CD006683-tbl-0008">Table 6</a>). </p> <p>The majority of trials followed up to two months or less (23 studies). Five studies followed up to three months (<a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>; <a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>) and six studies followed up longer: 140 days (<a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a>), six months (<a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>) and 12 months (<a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>). <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> had a low follow‐up of 10 % at 12 months </p> <p><a href="#CD006683-tbl-0008">Table 6</a> shows the outcomes reported in the studies. </p> </section> </section> <section id="CD006683-sec-0069"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD006683-sec-0130" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD006683-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD006683-fig-0002">Figure 2</a> </p> <div class="figure" id="CD006683-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006683-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006683-sec-0071"> <h4 class="title">Allocation</h4> <p>The majority of trialists did not report sufficient information to judge selection bias. These trials were marked as unclear for sequence generation and allocation concealment. Only two trials were judged at low risk of bias on both sequence generation and allocation concealment (<a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>). </p> <p>Eight trials reported a method of sequence generation judged to be likely to generate an unpredictable sequence. Some trials used random number tables (<a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>), other reports suggested computer‐generated random numbers or allocation schedules (<a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>), others referred to random numbers or randomly generated lists but did not specify how these were created (<a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>). </p> <p>Four trials reported a convincing method of allocation concealment (<a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>; <a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a>). In <a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> the assignment code was kept secret by a named individual until the end of the study; in <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> all investigators were masked to treatment group; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> used a central co‐ordination centre for allocation and in <a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> the allocation was prepared in such a way that neither investigators nor participants could identify the group. </p> <p>In three studies, we judged that the allocation was probably not concealed adequately (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>, <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>; <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>). </p> </section> <section id="CD006683-sec-0072"> <h4 class="title">Blinding</h4> <p>Ten studies were not masked and we judged them to be at high risk of both performance and detection bias (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a>; <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>; <a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a>; <a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a>; <a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a>; <a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>; <a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>; <a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>). </p> <p>Eight studies were masked and we judged them to be at low risk of both performance and detection bias (<a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>; <a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>; <a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>; <a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a>; <a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a>; <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>; <a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a>). </p> <p>Two studies that did not mask participants, stated explicitly that outcome assessors were masked (<a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>; <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>). </p> <p>For six studies, there was not enough information to judge the risk of either performance or detection bias (<a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a>; <a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a>; <a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a>; <a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>; <a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a>). </p> </section> <section id="CD006683-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>We judged five studies to be at high risk of attrition bias. In <a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>, there was variable follow‐up by outcome, and it was not clearly explained why. Some of the stated exclusion criteria for the study, such as inflammation after surgery, would have been related to the outcome. In <a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a>, follow‐up was unequal between study groups and reason for loss to follow‐up was not clearly reported. In <a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a>, 35 people withdrew before the end of the study because of intraoperative complications or they had, as only later recognised, an exclusion criteria as defined as maculopathy, diabetic retinopathy, prior uveitis or a systemic steroid therapy. It was not reported to which groups these patients belonged. In <a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>, there was very low follow‐up at six weeks, with 77/546 (14%) people followed‐up. In <a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> there was a high loss to follow‐up at 12 months: 38/100 (38%) in the NSAIDs group and 50/131 (38%) in the control group were followed‐up. </p> <p>We judged 11 studies to be at low risk of attrition bias. For the other studies there was not enough information to judge. </p> </section> <section id="CD006683-sec-0074"> <h4 class="title">Selective reporting</h4> <p>For most studies there was little information to judge selective outcome reporting because we did not have access to a trial registry entry or study protocol. We judged three studies to be at low risk of selective outcome reporting on the basis that the trial was prospectively registered and all outcomes prespecified on the clinical trials registry entry were reported (<a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a>; <a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>; <a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a>). For three studies it was clear that some outcomes were not fully reported and so we judged them to be at high risk of selective outcome reporting bias (<a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a>; <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>; <a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a>). </p> </section> </section> <section id="CD006683-sec-0075"> <h3 class="title" id="CD006683-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD006683-tbl-0001"><b>Summary of findings for the main comparison</b> NSAIDS plus steroids compared with steroids for the prevention of macular oedema after cataract surgery</a>; <a href="./full#CD006683-tbl-0002"><b>Summary of findings 2</b> NSAIDS compared with steroids for the prevention of macular oedema after cataract surgery</a> </p> <section id="CD006683-sec-0076"> <h4 class="title">Non‐steroidal anti‐inflammatory drugs plus steroids versus steroids</h4> <section id="CD006683-sec-0077"> <h5 class="title">Primary outcome</h5> <section id="CD006683-sec-0078"> <h6 class="title">Poor vision due to macular oedema</h6> <p>Five studies reported this outcome at three months (eyes = 1360) (<a href="./references#CD006683-fig-0005" title="">Analysis 1.1</a>). Follow‐up ranged from four weeks to two months. Two studies reported optical coherence tomography (OCT)‐confirmed macular oedema (MO) with visual acuity &lt; 6/9 in one study (<a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a>) but the level of visual impairment not defined in the other (<a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>). <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> defined the presence of clinical MO as visual acuity &lt;=20/40 and angiographic evidence of CMO. <a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> reported that none of the participants developed clinically significant macular oedema nor vision loss. <a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> reported that none of the participants developed clinically significant CMO as assessed via fundoscopy and the Amsler grid test. There was some evidence of selective reporting in <a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a>, which provided most of the information for the meta‐analysis. Data were only reported for the earlier follow‐up at days 21 to 60. Quote: "By day 121‐240 the incidence of clinical CME [cystoid macular edema] was less than 2% in all three groups and no significant differences were seen." </p> <p>People receiving non‐steroidal anti‐inflammatory drugs (NSAIDs) combined with steroids had a lower risk of poor vision due to macular oedema (MO) at three months after surgery compared with people receiving steroids alone. The pooled risk ratio (RR) was 0.41, 95% confidence interval (CI) 0.23 to 0.76; eyes = 1360; studies = 5. There was no evidence of any major inconsistency (I<sup>2</sup> = 5%). We judged this to be low‐certainty evidence (<a href="./full#CD006683-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded for risk of bias, as the trials were poorly reported and were largely at high or unclear risk of bias. We downgraded for indirectness, as the outcomes reported by the trials only approximated the outcome which we wished to collect, which was poor vision (best corrected visual acuity (BCVA) &lt; 6/9) due to MO. </p> <p>One study reported this outcome at 12 months (<a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a>). There was high attrition in this study (only 38% of eyes followed up) and only two events (RR 1.32, 95% CI 0.09 to 20.37; eyes = 88). We judged this to be very low‐certainty evidence, downgrading for risk of bias and imprecision (2 levels; <a href="./full#CD006683-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD006683-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD006683-sec-0080"> <h6 class="title">Quality of life/patient satisfaction</h6> <p>One study reported quality of life at 1 month after surgery using the Comparison of Ophthalmic Medications for Tolerability (COMTOL) questionnaire (<a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a>), No differences in the impact upon quality of life measures were identified between the treatment and control groups. The use of topical NSAIDs was also reported to have good tolerability and comparable side‐effect profile to placebo. However the data in this study were not fully reported and a response rate of only 60% was achieved with significant attrition with 65 out of 162 patients declining to answer the interview after surgery for "logistical reasons". </p> <p>Quote: "The global [health‐related quality of life] HRQOL questions showed no difference in the extent to which quality of life was affected by medication side effects between “not at all” and any reported effect (question 6; P = 0.8476). Regarding the extent quality of life was affected by activity limitations, there was no difference between “not at all” and any reported limitations (question 9; P = 0.8584). According to the COMTOL questionnaire, there was no difference in compliance between the 3 study groups (question 10; P = 0.3801). Most patients in all 3 groups reported being satisfied with the medication, and there was no difference between satisfied responses and dissatisfied responses (question 11; P = 0.4777)"). </p> </section> <section id="CD006683-sec-0081"> <h6 class="title">Central retinal thickness</h6> <p>Nine studies reported this outcome (eyes = 1112) (<a href="./references#CD006683-fig-0006" title="">Analysis 1.2</a>). Follow‐up ranged from one to two months. Six studies reported central retinal thickness at the end of the follow‐up period, three studies reported change in thickness from baseline. Trial results were inconsistent (I<sup>2</sup> = 87%). Results ranged from ‐30.9 µm in favour of NSAIDs plus steroids to +7.44µm in favour of steroids alone (<a href="./full#CD006683-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Six studies reported change in macular volume (eyes = 570) (<a href="./references#CD006683-fig-0007" title="">Analysis 1.3</a>). The pooled mean difference (MD) was ‐0.14 mm<sup>3</sup> (95% CI ‐0.21 to ‐0.07). There was some inconsistency (I<sup>2</sup> = 50%), mainly attributable to <a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a>. </p> </section> </section> <section id="CD006683-sec-0082"> <h5 class="title">Adverse effects</h5> <p>See <a href="#CD006683-tbl-0009">Table 7</a>. In the studies that reported adverse effects, no evidence of serious adverse events were seen. The most notable adverse effect associated with NSAID use was burning or stinging sensation. </p> <div class="table" id="CD006683-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people followed up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were 3 dropouts in the treatment group related to ketorolac corneal toxicity, most notably pain attributed to the drops." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: “One patient in the ketorolac group was hospitalized with a cardiovascular event and could not complete the follow‐up. Finally, 1 patient on nepafenac had side effects of ocular redness and irritation and could not continue with the study.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 "complications" not specified.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no serious treatment‐related adverse events or toxicity related to the use of nepafenac 0.1%." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "All patients reported pain and ocular discomfort lower than 1/10 on the visual analog scale at all time points." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Use of ketorolac 0.4% for 1 or 3 days provided decreased levels of patient discomfort intraoperatively and postoperatively. Intraoperatively, 3 days of ketorolac 0.4% provided significantly lower discomfort scores than with 1‐hour and placebo dosing (P &lt; 0.001). One day of ketorolac 0.4% also provided significantly reduced intraoperative discomfort scores than with 1‐hour dosing (P = 0.001) and placebo dosing (P &lt; 0.001). Postoperatively, 3 days of ketorolac 0.4% provided significantly lower discomfort scores than 1‐hour dosing or control dosing (P &lt; 0.001) (Figure 5). In addition, patients randomised to 1 or 3 days of ketorolac 0.4% were significantly less likely to require additional intravenous anesthesia (8% in each group) than patients in the control group (40%) (P = 0.008). Twenty percent of patients in the 1‐hour group required additional anesthesia for pain control." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No adverse events were noted in either group."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No major adverse effects were noted in either group." "Subjective tolerance of the two treatments was good and remained similar throughout the study, although a trend towards increased burning was seen in the diclofenac group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no adverse events except for a mild burning sensation in one patient in the ketorolac group; the symptom was tolerable and did not lead to discontinuation of the medication." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>between 2.5 and 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no complications that could be ascribed to the use of topical indomethacin other than minor stinging and burning noted by the patients." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no adverse events reported by patients using nepafenac."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs: 6 adverse effects: decreased lacrimation, conjunctivitis allergic, abnormal sensation in eye, vomiting (2), constipation. </p> <p>Steroid group: 9 adverse effects: decreased lacrimation, conjunctivitis allergic, retinal haemorrhage, keratoconjunctivitis sicca, chorioretinopathy, influenza, insomnia, diarrhoea, humeral fracture. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Diclofenac group: two patients were feeling burning after application of eye drops during the stationary care, for placebo: none. In both groups burning was reported later on in the examinations." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Treatment regimens were well tolerated with no evidence of relevant side effects."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No patient deaths were reported during the study. Overall, 13 patients reported other serious adverse events, none of which were related to treatment. Three of the serious adverse events reported in the vehicle group (cardiac failure congestive, coronary artery occlusion, and pancreatitis) led to patient discontinuation; no other serious adverse events led to discontinuation in either treatment group. Separate from the three patients who discontinued due to serious adverse events, four other patients discontinued study participation due to nonserious adverse events. Of these nonserious events, two reported instances of punctate keratitis (one in each treatment group) were assessed as being related to the study drugs. No instances of targeted adverse events (defined as corneal erosions) were reported during the study. </p> <p>Two reports of punctate keratitis and a single report of corneal epithelium defect were assessed as being related to treatment with nepafenac. A single report of punctate keratitis was assessed as being related to treatment with vehicle. No other ocular or nonocular adverse events reported in the study were assessed as being related to the study drugs. </p> <p>In both treatment groups, corneal staining and intraocular pressure were each generally similar at the presurgical baseline and at the day 90 visit (or early exit). Additionally, no safety issues or trends were identified based upon changes from baseline in fundus parameters (retina/macula/choroid and optic nerve) and ocular signs (inflammatory cells, aqueous flare, corneal oedema, and bulbar conjunctival injection). The study results indicate no new clinically relevant risks associated with increasing the dosing of nepafenac from 14 days to 90 days, even in the higher‐risk diabetic patient population." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "During the study, the mean severity of foreign‐body sensation, pain, photophobia, and tearing did not become more than mild (1 +) in any treatment group. This was also true of burning and stinging following treatment instillation (Figure 4). The severity of burning and stinging was significantly greater in the flurbiprofen group on days 4‐20 and 21‐60 and in the indomethacin group on days 1‐3, 4‐20, 21‐60, and 61‐120 than in the vehicle group. At day 1‐3, moderate to severe burning and stinging were reported by 7.0% (16/230) of the patients treated with flurbiprofen, 9.7% (23/237) of the patients treated with indomethacin, and 3.1% (7/224) of the patients treated with vehicle." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days (3 months mentioned but not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient withdrew because of burning.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no adverse side effects in either group."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote from translation: "40% reported a short burning after using indomethacin eye drops, only rare in patients of the placebo group. One patient had 6 weeks after treatment an allergic blepharitis due to indomethacin. Long‐term: 52 patients were followed for 6 months and 34 patients one year. 4 patients with indomethacin had visual acuity reduction because of a clinically new cystoid edema; 2 of these patients had spontaneous healing after 4‐6 weeks, the other 2 edema cases did not resolve. 2 patients had a new senile macula pathology, and 2 patients had a retinal detachment due to aphakia. Placebo: 2 patients still had an edema after 12 weeks, while one patient developed a new edema later." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No drug‐related adverse events were identified."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "The most commonly reported adverse events (investigator self‐report) in the ketorolac/steroid group were burning/stinging/tearing (4/268). Transient elevations in intraocular pressure (IOP) were the most commonly reported adverse event in the steroid group (3/278). There were two serious adverse events, both in the steroid group: one patient developed endophthalmitis and one patient died (cause determined to be unrelated to the study medication)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Mild to moderate punctuate epithelial defects of the cornea were found in both groups 3 weeks after treatment.Statistically significantly more patients in the nepafenac group than in the control group had corneal fluorescein staining (20 [26.7%] versus 8 [10.4%]) (PZ.0119). Headache was reported by 3 patients (4.0%) in the nepafenac group and 2 patients (2.6%) in the control group (PZ.9750). No other systemic or local untoward effects were recorded during 3 weeks of treatment in either study group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006683-sec-0083"> <h5 class="title">Resource use and costs</h5> <p>None of the studies commented on this.</p> </section> <section id="CD006683-sec-0084"> <h5 class="title">Additional National Institute for Health and Care Excellence (NICE) outcomes</h5> <section id="CD006683-sec-0085"> <h6 class="title">Macular oedema (MO) (clinically symptomatic, optical coherence tomography‐verified)</h6> <p>Twenty‐one studies reported this outcome (eyes = 3638) (<a href="./references#CD006683-fig-0008" title="">Analysis 1.4</a>). Follow‐up ranged from two weeks to just less than six months. </p> <p>Most studies reported "cystoid" macular oedema but it was not always clearly defined nor was it clear that it was clinically significant. Nine studies used OCT, although it was not always clear if the OCT was used to verify the MO; nine studies used fluorescein angiography, often using the <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification; clinical assessment for the presence of MO was made in two studies. </p> <p>There was an asymmetric funnel plot, suggesting that publication bias might be an issue (<a href="#CD006683-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD006683-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 NSAIDs plus steroids versus steroids, outcome: 1.4 Macular oedema." data-id="CD006683-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 NSAIDs plus steroids versus steroids, outcome: 1.4 Macular oedema. </p> </div> </div> </div> <p>People receiving NSAIDs combined with steroids had a lower risk of MO after surgery compared with people receiving steroids alone. The pooled RR was 0.40, 95% CI 0.32 to 0.49; I<sup>2</sup> = 0%. We judged this to be low‐certainty evidence (<a href="./full#CD006683-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded one level for risk of bias, as the studies were at unclear or high risk of bias and we downgraded one level for publication bias as an asymmetric funnel plot was suggestive of publication bias. We considered downgrading one level for indirectness, as the MO was not always OCT‐verified and it was not always clear if the MO was clinically significant but in the event did not as the size of the effect was strong. </p> </section> <section id="CD006683-sec-0086"> <h6 class="title">Inflammation</h6> <p>Three studies reported inflammation as a dichotomous outcome (<a href="./references#CD006683-fig-0009" title="">Analysis 1.5</a>). In <a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> there were no cases of "inflammatory cells greater than 1+ during first week of postoperative visits." In <a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a>, at day 28, inflammation, which was defined as corneal oedema or Tyndall reaction or conjunctival hyperemia was seen in two participants in the NSAIDs plus steroid group (RR 4.86, 95% CI 0.24 to 99.39); by day 35 this had disappeared. In <a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a>, 20 participants in the steroids group had inflammation defined as "Tyn granule +" compared to 0 participants in the NSAIDs plus steroids group at one month (RR 0.02, 95% CI 0.00 to 0.38). In view of such different results, we did not pool the data from these trials. </p> <p>Two studies reported flare in photons/millisecond (eyes = 216) (<a href="./references#CD006683-fig-0010" title="">Analysis 1.6</a>). The MD was ‐1.41 photons/millisecond in favour of NSAIDs plus steroids (95% CI ‐2.30 to ‐0.52), but there was some inconsistency between the two studies (I<sup>2</sup> = 49%). There was some evidence of skew for the control group of <a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> (mean/standard deviation (SD) &lt; 2). </p> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> reported "summed ocular inflammation score" which was the sum of the scores of cells and flare, scored against a maximum total score of 9. The inflammatory score at one month was 0.21 ± 0.42 in the bromfenac group and 0.32 ± 0.48 in the ketorolac group (P = 0.853). The score in the control group was 0.84 ± 0.76. </p> </section> <section id="CD006683-sec-0087"> <h6 class="title">Best corrected visual acuity</h6> <p>Ten studies reported BCVA (eyes = 1158) (<a href="./references#CD006683-fig-0011" title="">Analysis 1.7</a>). For <a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> change in BCVA was reported in letters. We converted this to logMAR score by multiplying by ‐0.02 and we estimated the SD from the P value. </p> <p>There was statistical heterogeneity (I<sup>2</sup> = 70%), and not all effect estimates were in the same direction, so we did not provide a pooled estimate. However, we note that most studies found differences clinically indistinguishable from no difference. </p> </section> </section> </section> <section id="CD006683-sec-0088"> <h4 class="title">Non‐steroidal anti‐inflammatory drugs versus steroids</h4> <section id="CD006683-sec-0089"> <h5 class="title">Primary outcome</h5> <section id="CD006683-sec-0090"> <h6 class="title">Poor vision due to macular oedema</h6> <p>None of the studies reported this outcome.</p> </section> </section> <section id="CD006683-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD006683-sec-0092"> <h6 class="title">Quality of life/patient satisfaction</h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD006683-sec-0093"> <h6 class="title">Central retinal thickness</h6> <p>Two studies reported central retinal thickness (<a href="./references#CD006683-fig-0012" title="">Analysis 2.1</a>). The pooled MD was ‐22.64 µm (95% CI ‐38.86 to ‐6.43; I<sup>2</sup> = 0%) in favour of NSAIDs. We judged this to be low‐certainty evidence (<a href="./full#CD006683-tbl-0002">summary of findings Table 2</a>). We downgraded one level for risk of bias, as the studies were at unclear or high risk of bias, and we downgraded one level for imprecision as the confidence intervals include a clinically unimportant effect. </p> </section> </section> <section id="CD006683-sec-0094"> <h5 class="title">Adverse effects</h5> <p>See <a href="#CD006683-tbl-0009">Table 7</a>. In the studies that reported adverse effects, no evidence of serious adverse events were seen. The most notable adverse effect associated with NSAID use was burning or stinging. </p> </section> <section id="CD006683-sec-0095"> <h5 class="title">Resource use and costs</h5> <p>None of the studies commented on this.</p> </section> <section id="CD006683-sec-0096"> <h5 class="title">Additional NICE outcomes</h5> <section id="CD006683-sec-0097"> <h6 class="title">Macular oedema (clinically symptomatic, optical coherence tomography‐verified)</h6> <p>Five studies reported this outcome (eyes = 520) (<a href="./references#CD006683-fig-0013" title="">Analysis 2.2</a>). All studies assessed MO using fluorescein angiography. The pooled RR was 0.27 (95% CI 0.18 to 0.41) in favour of NSAIDs. We note that for <a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> there may have been selective reporting ‐ data on MO were reported only at five weeks, but were not reported at the end of eight weeks follow‐up in that study. </p> <p>We judged this to be low‐certainty evidence (<a href="./full#CD006683-tbl-0002">summary of findings Table 2</a>). We downgraded one level for risk of bias, as the studies were at unclear or high risk of bias and we downgraded one level for publication bias because of an asymmetric funnel plot suggestive of publication bias (<a href="#CD006683-fig-0004">Figure 4</a>). We would not usually do a funnel plot with so few studies, but as the funnel plot for this outcome, for the comparison NSAIDs plus steroids versus steroids alone was asymmetric (<a href="#CD006683-fig-0003">Figure 3</a>), we felt that publication bias may be an issue here as well. </p> <div class="figure" id="CD006683-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 NSAIDs versus steroids, outcome: 2.2 Macular oedema." data-id="CD006683-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 NSAIDs versus steroids, outcome: 2.2 Macular oedema.</p> </div> </div> </div> </section> <section id="CD006683-sec-0098"> <h6 class="title">Inflammation</h6> <p>Five studies reported aqueous flare (eyes = 346) (<a href="./references#CD006683-fig-0014" title="">Analysis 2.3</a>). There was substantial inconsistency ( I<sup>2</sup> = 68%) and some evidence of skewed data so we did not report a pooled value. </p> </section> <section id="CD006683-sec-0099"> <h6 class="title">Best corrected visual acuity</h6> <p>Three studies reported BCVA (eyes = 220) (<a href="./references#CD006683-fig-0015" title="">Analysis 2.4</a>). There was statistical heterogeneity (I<sup>2</sup> = 84%) so we did not report a pooled value, but we note that all three studies found between group differences that were clinically indistinguishable from no difference. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006683-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006683-sec-0100"></div> <section id="CD006683-sec-0101"> <h3 class="title" id="CD006683-sec-0101">Summary of main results</h3> <p>See <a href="./full#CD006683-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006683-tbl-0002">summary of findings Table 2</a>. </p> <p>We identified 34 studies that were conducted in the Americas, Europe, the Eastern Mediterranean region and South‐East Asia. </p> <p>Over 5000 people were randomised in these trials. The majority of studies probably enrolled one eye per participant, a small subset (4 trials) enrolled a proportion of people with bilateral surgery. Twenty‐eight of these 34 studies compared non‐steroidal anti‐inflammatory drugs (NSAIDs) plus steroids with steroids alone. Six studies compared NSAIDs (on their own or with placebo) with steroids. A variety of NSAIDs were used, including ketorolac, diclofenac, nepafenac, indomethacin, bromfenac and pranopfen. Follow‐up ranged from one month to 12 months. The majority of studies (n = 23) followed up to two months or less. In general, the studies were poorly reported. We did not judge any of the studies at low risk of bias in all domains. </p> <p>There was low‐certainty evidence that people receiving topical NSAIDs in combination with steroids may have a lower risk of poor vision due to macular oedema (MO) at three months after cataract surgery compared with people receiving steroids alone (risk ratio (RR) 0.40, 95% confidence interval (CI) 0.27 to 0.61; eyes = 1360; studies = 5; I<sup>2</sup> = 5%). There were very little data for 12 months (only one study reported poor vision due to MO at this time point) and we judged this to have very low‐certainty evidence. Similarly, we judged the evidence on 'clinically symptomatic MO' to be low‐certainty. There was evidence on central retinal thickness at three months, but this was inconsistent (I<sup>2</sup> = 87%). Results ranged from ‐30.9 microns in favour of NSAIDs plus steroids to 7.44 microns in favour of steroids alone. Similarly, data on best corrected visual acuity (BCVA) were inconsistent. Nine out of 10 trials reporting this outcome found between‐group differences of less than 0.1 logMAR. </p> <p>None of the six studies comparing NSAIDs alone with steroids reported on poor vision due to MO at three months or 12 months. We judged the evidence on MO to be low‐certainty. There was low‐certainty evidence that mean central retinal thickness was lower in the NSAIDs group at three months (mean difference (MD) ‐22.64 microns, 95% CI ‐38.86 to ‐6.43; eyes = 121; studies = 2; I<sup>2</sup> = 0%). Two studies reported BCVA at three months, and the results of these trials were inconsistent, but both found differences of less than 0.1 logMAR between groups. </p> <p>Quality of life was only reported in one of the 34 studies, and it was not fully reported other than to comment on lack of differences between groups. In general, no major adverse events were noted ‐ the main consistent observation was burning or stinging. </p> </section> <section id="CD006683-sec-0102"> <h3 class="title" id="CD006683-sec-0102">Overall completeness and applicability of evidence</h3> <p>There were a relatively large number of trials, and these studies have a wide global range which means their results will be globally applicable. </p> <p>The included studies compared NSAIDs and steroids in cataract surgery using phacoemulsification, extracapsular cataract extraction (ECCE) and intracapsular cataract extraction (ICCE) surgical techniques. However, the more recent trials exclusively used phacoemulsification, which may make their findings less applicable to parts of the world where resources are less available and ECCE is standard. </p> <p>The aim of this review was to assess whether the use of NSAIDs had an impact on visual loss due to MO in the long‐term. The evidence is very sparse with respect to that question, with only one study with high attrition, reporting on visual loss due to MO at 12 months after surgery. This is clearly an important gap in the evidence. </p> <p>There are many trials looking at the short‐term effects of NSAIDs, but there is considerable variation in terms of types, doses and regimens of NSAIDs and steroids used. One aspect that we have not highlighted in this review, but has been discussed elsewhere (<a href="./references#CD006683-bbs2-0078" title="KimSJ , PatelSN , SternbergPJr . Routine use of nonsteroidal anti‐inflammatory drugs with corticosteroids in cataract surgery: Beneficial or redundant?. Ophthalmology2016;123(3):444‐6. ">Kim 2016a</a>), is the potency of the steroid used in the comparison group. Use of low potency steroids, such as fluorometholone 0.1%, may lead to an overestimate of the relative effect of NSAIDs. </p> <section id="CD006683-sec-0103"> <h4 class="title">Certainty of the evidence</h4> <p>We graded the evidence as low‐ to very low‐certainty. In general, the trials were poorly reported and it was difficult to judge the extent to which bias had been avoided. We did not judge any of the studies at low risk of bias for all domains. Many trials were not properly masked and, in a few studies, there were problems with attrition bias and selective outcome reporting. For outcomes that had more data we identified the possibility of publication bias with an asymmetric funnel plot. There were also problems with directness. For example, many studies reported "CMO" but were not clear whether or not this was 'clinically significant', or indeed what this meant in terms of whether it caused both symptoms and signs. And in many of the older studies this could not be verified by optical coherence tomography (OCT). </p> </section> </section> <section id="CD006683-sec-0104"> <h3 class="title" id="CD006683-sec-0104">Potential biases in the review process</h3> <p>We have made several modifications to the original protocol (see <a href="#CD006683-sec-0126">Differences between protocol and review</a>), but these were made before the data extraction and analysis phases of the review. </p> </section> <section id="CD006683-sec-0105"> <h3 class="title" id="CD006683-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>A recent systematic review and meta‐analysis has been published (<a href="./references#CD006683-bbs2-0094" title="WieldersLH , LambermontVA , SchoutenJS , van denBiggelaarFJ , WorthyG , SimonsRW , et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta‐analysis. American Journal of Ophthalmology2015;160:968‐81. ">Wielders 2015</a>). This review included 17 trials. The reason why they had fewer trials than the current review was because they only included studies of phacoemulsification cataract surgery and they excluded studies that did not report the incidence of cystoid macular oedema (CMO). </p> <p>The review by <a href="./references#CD006683-bbs2-0094" title="WieldersLH , LambermontVA , SchoutenJS , van denBiggelaarFJ , WorthyG , SimonsRW , et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta‐analysis. American Journal of Ophthalmology2015;160:968‐81. ">Wielders 2015</a> reported effect measures in the same order of magnitude as that suggested by this review, but because they reported odds ratios (ORs), rather than risk ratios (RRs), these effect estimates are exaggerated (further away from null). The authors concluded that the odds of CMO were reduced in people who were given NSAIDs, but they did not incorporate a judgement on the overall certainty (or quality) of the evidence in their conclusions, even though they had assessed the risk of bias in the included trials using two different methods. It is also notable that, although the abstract highlights the fact that 17 trials were included in the review, it is less clearly pointed out that the effect estimates were based on a relatively small subset of these trials. This review was subsequently criticised because it did not fully incorporate an assessment of visual loss due to CMO, because the conclusions were based on so few trials, and because of the likely exclusion of studies that did not report any events (<a href="./references#CD006683-bbs2-0077" title="KimSJ , JampelH . Prevention of cystoid macular edema after cataract surgery in non‐diabetic and diabetic patients: A systematic review and meta‐analysis. American Journal of Ophthalmology2016;161:221‐2. ">Kim 2016</a>). </p> <p>A report by the American Academy of Ophthalmology, also published in 2015, was more conservative in its conclusions (<a href="./references#CD006683-bbs2-0076" title="KimSJ , SchoenbergerSD , ThorneJE , EhlersJP , YehS , BakriSJ . Topical nonsteroidal anti‐inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology2015;122:2159‐68. ">Kim 2015</a>). This was a narrative review of the literature with no meta‐analysis, nor any assessment of the quality of the evidence. They concluded that NSAIDs reduced the incidence of CMO, and may increase visual recovery, depending on the treatment of the comparator group, however, they concluded that the use of NSAIDs did not alter long‐term (3 months) visual outcomes, a finding which is supported by the current review. </p> <p>One slightly older systematic review published in 2014, included 15 trials and did include an overall GRADE assessment of the certainty of the evidence, which they judged to be low‐ to moderate‐certainty for inflammation, low‐certainty for visual acuity and high‐certainty for CMO (<a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a>). This review again focused on phacoemulsification. It was restricted to the comparison of NSAIDs (on their own or with placebo) versus steroids alone. They cited the previously published protocol of this review justifying theirs as being different for these two reasons. They evaluated inflammation within one week of surgery and MO at any time point. There are some differences between the current review and <a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a> in terms of the included studies. This is because the searches for the current review were restricted to evidence relating to MO. However, the trials contributing data to the analysis of MO are similar in the two reviews. <a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a> included one study that we judged was probably not a randomised controlled trial (RCT) (<a href="./references#CD006683-bbs2-0043" title="MiyakeK , MasudaK , ShiratoS , OshikaT , EguchiK , HoshiH , et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Japanese Journal of Ophthalmology2000;44:58‐67. ">Miyake 2000</a>), and one study that we have included in the NSAIDs plus steroids comparison (<a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a>). The estimates of effect for MO reported in <a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a> and reported in this review are of a similar order of magnitude, although <a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a> reports a stronger effect. This can be attributed to the fact that, when extracting data from studies using the <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification, <a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a> considered Grades 2 to 3 as MO, whereas in the current review we considered Grades 1 to 3. The main difference between the reviews is in the grading of the certainty of the evidence. <a href="./references#CD006683-bbs2-0075" title="KesselL , TendalB , JorgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology2014;121:1915‐24. ">Kessel 2014</a> considered the evidence to be high‐certainty. It is not clearly stated why, but the footnote refers to a RR of 6, which we understand to mean that it is a strong effect, therefore they have not downgraded. We have considered the evidence on MO to be low‐certainty, downgrading for risk of bias and publication bias (<a href="./full#CD006683-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006683-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006683-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006683-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 NSAIDs plus steroids versus steroids, outcome: 1.4 Macular oedema." data-id="CD006683-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 NSAIDs plus steroids versus steroids, outcome: 1.4 Macular oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 NSAIDs versus steroids, outcome: 2.2 Macular oedema." data-id="CD006683-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 NSAIDs versus steroids, outcome: 2.2 Macular oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 1 Poor vision due to MO." data-id="CD006683-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 1 Poor vision due to MO.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 2 Central retinal thickness." data-id="CD006683-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 2 Central retinal thickness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 3 Total macular volume." data-id="CD006683-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 3 Total macular volume.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 4 Macular oedema." data-id="CD006683-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 4 Macular oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 5 Inflammation." data-id="CD006683-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 5 Inflammation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 6 Inflammation (flare)." data-id="CD006683-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 6 Inflammation (flare).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAIDs plus steroids versus steroids, Outcome 7 BCVA." data-id="CD006683-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 NSAIDs plus steroids versus steroids, Outcome 7 BCVA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NSAIDs versus steroids, Outcome 1 Central retinal thickness." data-id="CD006683-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 NSAIDs versus steroids, Outcome 1 Central retinal thickness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NSAIDs versus steroids, Outcome 2 Macular oedema." data-id="CD006683-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 NSAIDs versus steroids, Outcome 2 Macular oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NSAIDs versus steroids, Outcome 3 Inflammation (flare)." data-id="CD006683-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 NSAIDs versus steroids, Outcome 3 Inflammation (flare).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006683-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/urn:x-wiley:14651858:media:CD006683:CD006683-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_t/tCD006683-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NSAIDs versus steroids, Outcome 4 BCVA." data-id="CD006683-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 NSAIDs versus steroids, Outcome 4 BCVA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/media/CDSR/CD006683/image_n/nCD006683-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006683-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAIDS plus steroids compared with steroids for the prevention of macular oedema after cataract surgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NSAIDs plus steroids compared with steroids for the prevention of macular oedema after cataract surgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people having cataract surgery </p> <p><b>Setting:</b> eye hospital<br/> <b>Intervention:</b> NSAIDs plus steroids<br/> <b>Comparison:</b> steroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs plus steroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision due to MO at 3 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (17 to 56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.41<br/> (0.23 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1360<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision due to MO at 12 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (2 to 407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.32<br/> (0.09 to 20.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life at 3 months after surgery</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in 1 study only using COMTOL questionnaire. Data not fully reported but no significant differences in terms of quality of life, compliance and satisfaction scores. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central retinal thickness at 3 months after surgery;<br/> assessed with OCT </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1021<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial results were inconsistent (I<sup>2</sup> = 87%). Results ranged from ‐30.9 microns in favour of NSAIDs plus steroids to +7.44 microns in favour of steroids alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In general, no major adverse effects were noted. The main consistent observation was burning or stinging sensation with use of NSAID drops. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MO at 3 months after cataract surgery, clinically symptomatic,<br/> assessed with OCT </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000 (42 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40 (CI 0.32 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3638</p> <p>(21 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA at 3 months after surgery;<br/> assessed with logMAR<br/> scale from: ‐1.3 to 1.3 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1158<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial results were inconsistent (I<sup>2</sup> = 70%), but all except one study found differences less than 0.1 logMAR, i.e. clinically indistinguishable from no difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BCVA</b> : best corrected visual acuity; <b>CI:</b> confidence interval; <b>MO</b> : macular oedema; <b>NSAID</b> : non‐steroidal anti‐inflammatory drug; <b>OCT</b> : optical coherence tomography; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 level for risk of bias: studies at unclear or high risk of bias.<br/> <sup>2</sup> Downgraded 1 level for indirectness: extent of visual loss not always clearly defined.<br/> <sup>3</sup> Downgraded 2 levels for imprecision: Only 2 events.<br/> <sup>4</sup> Downgraded 1 level for publication bias: asymmetric funnel plot suggestive of publication bias. </p> <p><sup>5</sup> We considered downgrading an additional 1 level for indirectness as the MO was not always OCT‐verified and it was not always clear if the MO was clinically symptomatic. However, we did not do so partly because the size of the effect was quite strong. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAIDS plus steroids compared with steroids for the prevention of macular oedema after cataract surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006683-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NSAIDS compared with steroids for the prevention of macular oedema after cataract surgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NSAID</b> s<b>compared with steroids for the prevention of macular oedema after cataract surgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people having cataract surgery<br/> <b>Setting:</b> eye hospital<br/> <b>Intervention:</b> NSAIDs<br/> <b>Comparison:</b> steroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with steroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision outcome due to MO at 3 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor vision outcome due to MO at 12 months after surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life at 3 months after surgery</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central retinal thickness at 3 months after surgery;<br/> assessed with OCT </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean central retinal thickness at 3 months after surgery was 228 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 22.64 microns lower<br/> (38.86 lower to 6.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>488<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study had 2 unspecified complications in 142 participants, 2 studies reported that no adverse events were noted in either group, 1 study (55 people) mentioned 15 mild adverse effects but unclear if related to treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MO at 3 months after cataract surgery; clinically symptomatic<br/> assessed with OCT </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> <p>(23 to 53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.27 (0.18 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA at 3 months after surgery;<br/> assessed with logMAR<br/> scale from: ‐1.3 to 1.3 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial results were inconsistent (I<sup>2</sup> = 84%), but all studies found differences less than 0.1 logMAR, </p> <p>i.e. clinically indistinguishable from no difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BCVA</b> : best corrected visual acuity; <b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>MO</b> : macular oedema; <b>NSAID</b> : non‐steroidal anti‐inflammatory drug; <b>OCT</b> : optical coherence tomography; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 level for risk of bias: studies at unclear or high risk of bias.<br/> <sup>2</sup> Downgraded 1 level for publication bias: asymmetric funnel plot suggestive of publication bias. </p> <p><sup>3</sup> We considered downgrading 1 level for indirectness as the MO was not always OCT‐verified and not always clear if it was clinically symptomatic however we did not do so, partly because the effect was strong.<br/> <sup>4</sup> Downgraded 1 level for imprecision: confidence intervals include clinically unimportant effect.<br/> <sup>5</sup> Downgraded 1 level for inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NSAIDS compared with steroids for the prevention of macular oedema after cataract surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">'Risk of bias' assessment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Domain</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unclear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computer‐generated list, random table, other method of generating random list.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported how list was generated. Trial may be described as “randomised” but with no further details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alternate allocation, date of birth, records (these RCTs should be excluded).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central centre (web/telephone access), sealed opaque envelopes.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported how allocation administered. Trial may be described as “randomised” but with no further details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator involved in treatment allocation or treatment allocation clearly not masked. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of participants and personnel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearly stated that participants and personnel not aware of which treatment received.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Described as “double‐blind” with no information on who was masked.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label or no information on masking. We assume that in absence of reporting on this outcome, patients and personnel were not masked. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of outcome assessors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearly stated that outcome assessors were masked.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Described as “double‐blind” with no information on who was masked.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label or no information on masking. We assume that in absence of reporting on this outcome, assessors were not masked. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data less than 20% (i.e. more than 80% follow‐up) and equal follow‐up in both groups and no obvious reason why loss to follow‐up should be related to outcome. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up not reported or missing data &gt; 20% (i.e. follow‐up &lt; 80%) but follow‐up equal in both groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up different in each group and/or related to outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective outcome reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All outcomes in protocol and/or trial registry entry are reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No access to protocol or trial registry entry.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes in protocol and/or trial registry entry selectively reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other sources of bias</p> <p>Note: we did not identify any important sources of other bias so this domain is omitted from the risk of bias tables. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No other source of bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial stopped early due to poor recruitment.</p> <p>Baseline imbalance, but not clear that it is important.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial stopped early because of outcome.</p> <p>Important baseline imbalance that might have an effect on the results.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">'Risk of bias' assessment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Open‐label</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funding sources</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Declaration of interest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial registration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abstract only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00335439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01395069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry/Non‐Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00494494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00782717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada (8 sites) and Germany (2 sites)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT02084576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00348244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry/Non‐industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported; no CoI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not registered</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CoI: conflict of interest</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Participant numbers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people randomised (missing data imputed)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of eyes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of eyes estimated (missing data imputed)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people followed up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people followed up (missing data imputed)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eyes per person enrolled in the trial</b> </p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 eyes of 98 people</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 eyes of 70 patients</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably one</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 eyes of 210 people</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye; right eye only</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 eyes of 198 people</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>*For studies that did not report the number randomised, we have estimated this from the number followed up. For studies that did not report the number followed up, we have estimated this from the numbers randomised. Number of eyes estimated assuming one eye per person, if not clearly stated otherwise. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Participant numbers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Participant characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% female</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% with uveitis</b> </p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 to 92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but low risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"low risk population"</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but people with DR excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 to 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 to 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 to 97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 to 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 to 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 to 86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but people with DR excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 to 87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 to 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ but people with DR excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 to 92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with diabetes excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% people with uveitis excluded</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>DR: diabetic retinopathy</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Participant characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of cataract surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Steroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo in comparator group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of placebo</b> </p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%, Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sterile saline drops</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1% (combined with tobramycin 0.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1%,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamethasone (with fradiomycin sulfate) followed by fluorometholone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac 0.1%,</p> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone acetate 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE and phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (in combination with neomycin sulfate, polymyxin B sulfate) for 4 days followed by dexamethasone alone for 4 weeks followed by fluorometholone for at least 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorometholone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorometholone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids/NSAIDs versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamethasone 0.1%, fluorometholone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1% (combined with chloramphenicol 0.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flurbiprofen 0.03%</p> <p>Indomethacin 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dextran 70/hypromellose</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%, Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ECCE/ICCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with either chloramphenicol or neomycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromfenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> fluorometholone 0.1% and dexamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICCE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids given as part of standard care, not specified exactly what</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indomethacin 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepafenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artifical tears</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phacoemulsification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs plus steroids versus steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pranoprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (combined with tobramycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ECCE: extracapsular cataract extraction<br/> ICCE: intracapsular cataract extraction<br/> NSAIDs: non‐steroidal anti‐inflammatory drugs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Poor vision outcome due to MO</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life/patient satisfaction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Central retinal thickness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CMO</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BCVA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Additional outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0005" title="">Analysis 1.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No analysis; only one study reported this</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0006" title="">Analysis 1.2</a>; <a href="./references#CD006683-fig-0012" title="">Analysis 2.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="#CD006683-tbl-0009">Table 7</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0008" title="">Analysis 1.4</a>; <a href="./references#CD006683-fig-0013" title="">Analysis 2.2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0009" title="">Analysis 1.5</a>; <a href="./references#CD006683-fig-0010" title="">Analysis 1.6</a>; <a href="./references#CD006683-fig-0014" title="">Analysis 2.3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0011" title="">Analysis 1.7</a>; <a href="./references#CD006683-fig-0015" title="">Analysis 2.4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-fig-0007" title="">Analysis 1.3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT used but CMO not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in total macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COMTOL questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change reported but not possible to calculate SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in total macular volume; change in average macular cube thickness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification (at 5 weeks only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser flare‐cell photometry, mean value of anterior chamber flare (photons/millisecond)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser flare‐cell photometry, mean value of anterior chamber flare reported (photons) but was not possible to calculate SD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "None of the patients developed clinically significant macular oedema associated with vision loss" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only reported CMO associated with vision loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Inflammatory cells greater than 1+ during first week of postoperative visits"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundoscopy and Amsler grid test</p> <p>Quote: "no evidence of clinically significant CME"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No evidence of clinically significant CME was detected in any patient via fundoscopy and the Amsler grid test" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal oedema or Tyndall reaction or conjunctival hyperaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Clinically significant CME" but otherwise not defined, at 2 weeks only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean inflammation score" but was not possible to calculate SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value but could not extract data on SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical examination, unclear if OCT‐verified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anterior chamber flare values, photon count per millisecond</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Inflammatory score" (sum of anterior chamber cells and flare grade"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between 2.5 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT, "clinically apparent" CME otherwise not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in foveal thickness, change in macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unit of measurement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flare (photons/millisec), final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in logMAR BCVA, categorical 3+, 2, 1 lines increase and no change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Obvious CMO confirmed by OCT"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aqueous flare (photons/millisecond)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"&gt;= 30% increase in central subfield macular thickness from baseline"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flare mentioned but data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corrected BCVA loss of more than 5 letters from day 7 postop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 21 to 60, MO = positive angiography and visual acuity &lt;= 20/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using classification***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity but not reported by treatment group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days (3 months mentioned but not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported but no mean/SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with &gt; 10% increase in retinal thickness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography 0 no leakage (CME absent),1 oedema less than perifoveal, 2 mild perifoveal oedema, 3 moderate perifoveal oedema (approx. 1 disc diameter), 4 severe perifoveal oedema plus drop of 1 line of Snellen acuity since second postoperative week defined as "clinically significant" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value (at 30 days only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography using <a href="./references#CD006683-bbs2-0080" title="MiyakeK . Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie1977;203:81‐8. ">Miyake 1977</a> classification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Snellen acuity only, not included in analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐confirmed CMO with "visual impairment" (not specified cutpoint)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CME was defined as central retinal<br/> thickness &gt; 250 μm and the presence of intraretinal cystoid space<br/> beneath the foveal, with the diagnosis confirmed by the same retinal<br/> specialist" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean photon count values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐confirmed CMO with visual acuity &lt; 6/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical and OCT‐based</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CMO on fluorescein angiography with visual acuity &lt; 6/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluorescein angiography, evidence but not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Slight fluorescein leakage<br/> into the cystic space without enclosing the entire central<br/> fovea or complete fluorescein accumulation in the cystic<br/> space was diagnosed as angiographic CME" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐verified but not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean anterior chamber flare reported in figure but no SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LogMAR, final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in total macular volume</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OCT‐verified but not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tyn granule +</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>BCVA: best corrected visual acuity<br/> CME: cystoid macular oedema (edema)<br/> CMO: cystoid macular oedema<br/> COMTOL: Comparison of Ophthalmic Medications for Tolerability (questionnaire)<br/> MO: macular oedema<br/> OCT: ocular coherence tomography<br/> SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006683-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people followed up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0001" title="AlmeidaDR , JohnsonD , HollandsH , SmallmanD , BaxterS , EngKT , et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] ">Almeida 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were 3 dropouts in the treatment group related to ketorolac corneal toxicity, most notably pain attributed to the drops." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0002" title="AlmeidaDR , KhanZ , XingL , BakarSN , RahimK , UrtonT , et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] El‐DefrawySR , AlmeidaDR . Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal2000;61:29. ">Almeida 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: “One patient in the ketorolac group was hospitalized with a cardiovascular event and could not complete the follow‐up. Finally, 1 patient on nepafenac had side effects of ocular redness and irritation and could not continue with the study.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0003" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] ">Asano 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 "complications" not specified.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0004" title="BrownRM , RobertsCW . Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses)1996;21(1):13‐6. ">Brown 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0005" title="Cervantes‐CosteG , Sánchez‐CastroYG , Orozco‐CarrollM , Mendoza‐SchusterE , Velasco‐BaronaC . Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology2009;3(1):219‐26. ">Cervantes‐Coste 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no serious treatment‐related adverse events or toxicity related to the use of nepafenac 0.1%." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0006" title="ChatziralliIP , PapazisisL , SergentanisTN . Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica2011;225(2):89‐94. [DOI: 10.1159/000317067] ">Chatziralli 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "All patients reported pain and ocular discomfort lower than 1/10 on the visual analog scale at all time points." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0007" title="DonnenfeldED , PerryHD , WittpennJR , SolomonR , NattisA , ChouT . Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] ">Donnenfeld 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Use of ketorolac 0.4% for 1 or 3 days provided decreased levels of patient discomfort intraoperatively and postoperatively. Intraoperatively, 3 days of ketorolac 0.4% provided significantly lower discomfort scores than with 1‐hour and placebo dosing (P &lt; 0.001). One day of ketorolac 0.4% also provided significantly reduced intraoperative discomfort scores than with 1‐hour dosing (P = 0.001) and placebo dosing (P &lt; 0.001). Postoperatively, 3 days of ketorolac 0.4% provided significantly lower discomfort scores than 1‐hour dosing or control dosing (P &lt; 0.001) (Figure 5). In addition, patients randomised to 1 or 3 days of ketorolac 0.4% were significantly less likely to require additional intravenous anesthesia (8% in each group) than patients in the control group (40%) (P = 0.008). Twenty percent of patients in the 1‐hour group required additional anesthesia for pain control." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0008" title="ElsawyMF , BadawiN , KhairyHA . Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology2013;7:1245‐9. [DOI: http://dx.doi.org/10.2147/OPTH.S39188] ">Elsawy 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0009" title="EndoN , KatoS , HaruyamaK , ShojiM , KitanoS . Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica2010;88(8):896‐900. [DOI: 10.1111/j.1755‐3768.2009.01582.x] KitanoS , EndoN , ShojiM , HaruyamaK , KatoS . Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science2008;49(3):ARVO E‐abstract 3470. ">Endo 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No adverse events were noted in either group."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0010" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery1997;23(8):1183‐9. ">Italian Diclofenac Study Group 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No major adverse effects were noted in either group." "Subjective tolerance of the two treatments was good and remained similar throughout the study, although a trend towards increased burning was seen in the diclofenac group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0011" title="JungJW , ChungBH , KimEK , SeoKY , KimTI . The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal2015;56:1671‐7. ">Jung 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no adverse events except for a mild burning sensation in one patient in the ketorolac group; the symptom was tolerable and did not lead to discontinuation of the medication." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0012" title="KraffMC , SandersDR , JampolLM , PeymanGA , LiebermanHL . Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982;89(8):885‐90. ">Kraff 1982</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>between 2.5 and 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no complications that could be ascribed to the use of topical indomethacin other than minor stinging and burning noted by the patients." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0013" title="LiM‐C , YangX‐R , LiuF , ShaoD‐P , LiY‐B . Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672‐5123.2011.09.039] ">Li 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0014" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] ">Mathys 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no adverse events reported by patients using nepafenac."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0015" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology &amp; Visual Science2007;48(12):5647‐52. [DOI: 10.1167/iovs.07‐0262] ">Miyake 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0016" title="MiyakeK , OtaI , MiyakeG , NumagaJ . Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] ">Miyake 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs: 6 adverse effects: decreased lacrimation, conjunctivitis allergic, abnormal sensation in eye, vomiting (2), constipation. </p> <p>Steroid group: 9 adverse effects: decreased lacrimation, conjunctivitis allergic, retinal haemorrhage, keratoconjunctivitis sicca, chorioretinopathy, influenza, insomnia, diarrhoea, humeral fracture. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0017" title="MiyanagaM , MiyaiT , NejimaR , MaruyamaY , MiyataK , KatoS . Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica2009;87(3):300‐5. [DOI: 10.1111/j.1755‐3768.2008.01433.x] ">Miyanaga 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0018" title="MoschosMM , ChatziralliIP , PantazisP , RouvasAA , SergentanisTN . Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] ">Moschos 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0019" title="QuentinCD , Behrens‐BaumannW , GausW . Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie1989;86(6):546‐9. ">Quentin 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Diclofenac group: two patients were feeling burning after application of eye drops during the stationary care, for placebo: none. In both groups burning was reported later on in the examinations." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0020" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794‐9. TorrazzaC , RossettiL , CastoldiD , BujtarE , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology &amp; Visual Science1995;36:ARVO E‐Abstract 3769. ">Rossetti 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Treatment regimens were well tolerated with no evidence of relevant side effects."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0021" title="PollackA , NarvekarA , AdewaleA , SinghR . A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica2014;232:20‐1. PollackA , SagerD , SinghR . Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica2014;232:20. SinghR , AlpernL , JaffeGJ , LehmannRP , LimJ , ReiserHJ , et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] ">Singh 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No patient deaths were reported during the study. Overall, 13 patients reported other serious adverse events, none of which were related to treatment. Three of the serious adverse events reported in the vehicle group (cardiac failure congestive, coronary artery occlusion, and pancreatitis) led to patient discontinuation; no other serious adverse events led to discontinuation in either treatment group. Separate from the three patients who discontinued due to serious adverse events, four other patients discontinued study participation due to nonserious adverse events. Of these nonserious events, two reported instances of punctate keratitis (one in each treatment group) were assessed as being related to the study drugs. No instances of targeted adverse events (defined as corneal erosions) were reported during the study. </p> <p>Two reports of punctate keratitis and a single report of corneal epithelium defect were assessed as being related to treatment with nepafenac. A single report of punctate keratitis was assessed as being related to treatment with vehicle. No other ocular or nonocular adverse events reported in the study were assessed as being related to the study drugs. </p> <p>In both treatment groups, corneal staining and intraocular pressure were each generally similar at the presurgical baseline and at the day 90 visit (or early exit). Additionally, no safety issues or trends were identified based upon changes from baseline in fundus parameters (retina/macula/choroid and optic nerve) and ocular signs (inflammatory cells, aqueous flare, corneal oedema, and bulbar conjunctival injection). The study results indicate no new clinically relevant risks associated with increasing the dosing of nepafenac from 14 days to 90 days, even in the higher‐risk diabetic patient population." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0022" title="SolomonLD . Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery1995;21(1):73‐81. SolomonLD , BoyanerD , BreslinCW , DemcoTA , FabianE , LeBlancRP , et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology1990:120. ">Solomon 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "During the study, the mean severity of foreign‐body sensation, pain, photophobia, and tearing did not become more than mild (1 +) in any treatment group. This was also true of burning and stinging following treatment instillation (Figure 4). The severity of burning and stinging was significantly greater in the flurbiprofen group on days 4‐20 and 21‐60 and in the indomethacin group on days 1‐3, 4‐20, 21‐60, and 61‐120 than in the vehicle group. At day 1‐3, moderate to severe burning and stinging were reported by 7.0% (16/230) of the patients treated with flurbiprofen, 9.7% (23/237) of the patients treated with indomethacin, and 3.1% (7/224) of the patients treated with vehicle." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0023" title="TauberS , GesslerJ , ScottW , PetersonC , HamletP . The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 683. ">Tauber 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days (3 months mentioned but not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0024" title="TiclyFG , LiraRP , ZanettiFR , MachadoMC , RodriguesGB , ArietaCE . Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics2014;30(6):495‐501. [DOI: http://dx.doi.org/10.1089/jop.2013.0214] ">Ticly 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient withdrew because of burning.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0025" title="TuncM , SaatciOA , ErginMH , ErginS . Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma1999;31(1):27‐32. ">Tunc 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0026" title="TzelikisPF , VieiraM , HidaWT , MottaAF , NakanoCT , NakanoEM , et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology2015;99:654‐8. ">Tzelikis 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no adverse side effects in either group."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0027" title="Umer‐BlochU . Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde1983;183(6):479‐84. [DOI: 10.1055/s‐2008‐1054988] Umer‐BlochU . Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde1983;182(5):495‐6. ">Umer‐Bloch 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote from translation: "40% reported a short burning after using indomethacin eye drops, only rare in patients of the placebo group. One patient had 6 weeks after treatment an allergic blepharitis due to indomethacin. Long‐term: 52 patients were followed for 6 months and 34 patients one year. 4 patients with indomethacin had visual acuity reduction because of a clinically new cystoid edema; 2 of these patients had spontaneous healing after 4‐6 weeks, the other 2 edema cases did not resolve. 2 patients had a new senile macula pathology, and 2 patients had a retinal detachment due to aphakia. Placebo: 2 patients still had an edema after 12 weeks, while one patient developed a new edema later." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0028" title="WangQW , YaoK , XuW , ChenPQ , ShentuXC , XieX , et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica2013;229(4):187‐94. [DOI: 10.1159/000346847] ">Wang 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No drug‐related adverse events were identified."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0029" title="RochaG . A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology2009;10(2):92‐3. WittpennJ , SilversteinSM , HunkelerJD , SchechterB , PriceFW , ChuYR , et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology2006:197. WittpennJR , SilversteinS , HeierJ , KenyonKR , HunkelerJD , EarlM , et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology2008;146(4):554‐60. [DOI: http://dx.doi.org/10.1016/j.ajo.2008.04.036] ">Wittpenn 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "The most commonly reported adverse events (investigator self‐report) in the ketorolac/steroid group were burning/stinging/tearing (4/268). Transient elevations in intraocular pressure (IOP) were the most commonly reported adverse event in the steroid group (3/278). There were two serious adverse events, both in the steroid group: one patient developed endophthalmitis and one patient died (cause determined to be unrelated to the study medication)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0030" title="YannuzziLA , LandauAN , TurtzAI . Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981;88(9):947‐54. ">Yannuzzi 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0031" title="YavasGF , OztürkF , KüsbeciT . Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] ">Yavas 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0032" title="YungCW , HuiSL , WangJ , GaoH , PerachaMO , PrattLM , et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology2007:208. ">Yung 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0033" title="ZaczekA , ArtzenD , LaurellCG , SteneviU , MontanP . Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery2014;40(9):1498‐505. [DOI: http://dx.doi.org/10.1016/j.jcrs.2013.12.023] ">Zaczek 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Mild to moderate punctuate epithelial defects of the cornea were found in both groups 3 weeks after treatment.Statistically significantly more patients in the nepafenac group than in the control group had corneal fluorescein staining (20 [26.7%] versus 8 [10.4%]) (PZ.0119). Headache was reported by 3 patients (4.0%) in the nepafenac group and 2 patients (2.6%) in the control group (PZ.9750). No other systemic or local untoward effects were recorded during 3 weeks of treatment in either study group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006683-bbs2-0034" title="ZhangH‐Y , ZhuS‐Q . Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology2008;8(7):1370‐2. ">Zhang 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects not reported.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/full#CD006683-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006683-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAIDs plus steroids versus steroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Poor vision due to MO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.23, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.09, 20.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Central retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 FInal value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total macular volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Macular oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.32, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Inflammation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Inflammation (flare) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.41 [‐2.30, ‐0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 BCVA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Final value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAIDs plus steroids versus steroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006683-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NSAIDs versus steroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Central retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.64 [‐38.86, ‐6.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Macular oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.18, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Inflammation (flare) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 BCVA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NSAIDs versus steroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006683.pub3/references#CD006683-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006683.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006683-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006683-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="pt#CD006683-note-0005">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD006683-note-0004">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006683\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006683\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006683\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006683\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006683\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006683.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006683.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006683.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006683.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006683.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718368667"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006683.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718368671"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006683.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dce9f1ef0935f',t:'MTc0MDcxODM2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 